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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
Insulin resistance in brain disorders 
 
The relationship between metabolic and neuropsychiatric diseases has been a focus of intensive 
investigation in recent years.  Indeed, significant overlap exists, in terms of both disease 
comorbidity and regulatory mechanisms, between cardiovascular, glucose control, and nervous 
system disorders.  Impaired glucose tolerance, for example, is frequently encountered in patients 
with schizophrenia (Bushe and Holt 2004; Scheen and De Hert 2007; van Winkel, van Os et al. 
2008; Ferentinos and Dikeos 2012).  While this association is generally attributed to the side 
effects of antipsychotic medications, recent findings demonstrate that even first-episode, 
medication-naïve patients have higher rates of glucose intolerance (Ryan, Collins et al. 2003; 
Venkatasubramanian, Chittiprol et al. 2007; Verma, Subramaniam et al. 2009).  Additional 
findings suggest the interrelatedness of metabolic disease and mental illness extends beyond 
schizophrenia.  For example, cardiovascular disease, a key component of metabolic syndrome, is 
more frequently encountered in the bipolar population, and patients with Type 1 diabetes 
commonly suffer from comorbid depression (Anderson, Freedland et al. 2001; Grey, Margaret et 
al. 2002; Barnard, Skinner et al. 2006; Swartz and Fagiolini 2012; Vancampfort, Vansteelandt et 
al. 2013; Westman, Hallgren et al. 2013).  The association between metabolic disease and brain 
disorders additionally extends beyond psychiatry, as recent evidence indicates that insulin 
resistance (IR) may in itself be a risk factor for both Alzheimer’s and Parkinson’s disease (Hu, 
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Jousilahti et al. 2007; Li and Hölscher 2007).  Imaging studies provide insight into 
neuroanatomic foci underlying the relationship between metabolic and neuropsychiatric 
disorders, as patients with IR demonstrate global cerebral atrophy, particularly in frontal cortical 
and hippocampal regions (Bruehl, Sweat et al. 2011; Yates, Sweat et al. 2012).   
Given historical treatments of schizophrenia, the recent clinical and neuroimaging 
associations between metabolic and neuropsychiatric illness are particularly intriguing.   In the 
pre-phenothiazine era, induction of coma with high doses of insulin was a common treatment for 
patients with severe cases of psychosis.  While the safety and efficacy of such approaches were 
attributed to low powered studies and anecdotal evidence at the time, the paucity of alternatives 
allowed insulin shock therapy to become an important part of schizophrenia treatment before the 
advent of antidopaminergic medications (Doroshow 2007).  While insulin coma naturally 
became extinct as newer, safer medications arose, the emerging relationship between metabolic 
and neuropsychiatric disease suggests that understanding insulin signaling in the brain may yield 
insights into the mechanisms of nervous system disorders. 
 
Mechanisms of insulin resistance 
 
IR, as it is clinically defined, refers to an impaired ability of a known amount of exogenous or 
endogenous insulin to trigger glucose uptake and utilization compared to normal individuals 
(Lebovitz 2001).  At a molecular level, insulin affects glucose metabolism by increasing the cell 
surface expression of the glucose transporter, enhancing the net function of glycogen synthase, 
and other mechanisms (Lebovitz 2001).  IR is hypothesized to occur when there is dysfunction in 
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the components of insulin signaling that are responsible for communication between insulin and 
downstream glucose-disposal mechanisms (Shulman 2000; Kahn, Hull et al. 2006).     
IR, as it refers to the central nervous system, has different implications than in the 
periphery, as glucose uptake in the CNS is not insulin-dependent.  Rather, IR in the CNS is more 
accurately conceptualized as impairment in the ability of insulin to activate its intracellular 
effectors.  There are many potential signaling components, therefore, that can serve as a 
molecular basis for IR.   
The initiating component in the insulin signaling cascade occurs when insulin itself binds 
to its receptor, a surface bound-protein that is part of the receptor tyrosine kinase (RTK) family.  
Receptor stimulation leads to phosphorylation of tyrosine moieties on downstream proteins, 
including both the receptors themselves and scaffolding proteins like the insulin receptor 
substrate (IRS). The tyrosine-phosphorylated protein products of receptor stimulation interact 
with the SH2 domain on growth factor sensitive isoforms of protein phosphoinositide 3-kinase 
(PI3K) (Rameh and Cantley 1999).  PI3K then catalyzes phosphorylation of phosphoinositides at 
the 3-position in the inositol ring, leading to additional phosphorylation steps that generate 
phosphatidylinositol (3,4,5)-triphosphate (PIP3) from phosphatidylinositol (4,5)-biphosphate 
(PIP2).  These phosphorylated phosphoinositide byproducts interact with the Pleckstrin 
homology (PH) domain of the protein kinase Akt, causing membrane translocation of Akt 
through the formation of salt bridges.  Once at the membrane, the upstream kinases 
phosphoinositide-dependent kinase 1 (PDK1) and mammalian target of rapamycin complex 2 
(mTORC2) act directly on Akt to phosphoryate this kinase at the Threonine-308 (T308) and 
Serine-473 (S473) residues.  These phosphorylation steps increase the ability of Akt to 
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phosphorylate downstream substrates (Rameh and Cantley 1999).  A schematic depicting the 
insulin/Akt signaling pathway is depicted in Fig. 1. 
Given the multitude of insulin signaling effectors, the exact mechanisms underlying IR at 
a physiological level are likely to be multifactorial at a molecular level.  Indeed, there is some 
support for IR at levels including IRS, PI3K, and Akt itself (Pessin and Saltiel 2000; Cho, Mu et 
al. 2001; Vosseller, Wells et al. 2002).  In addition to the Akt pathway, parallel signaling 
pathways stimulated in response to insulin are also potential mechanisms of IR, like mitogen-
activated protein kinase (MAPK) and extracellular regulated kinase (ERK) (Sesti 2006; Asano, 
Fujishiro et al. 2007).  In terms of isolating a molecular link between IR and neuropsychiatric 
disease, however, Akt is a promising mechanism for further investigation, as Akt dysfunction, in 
itself, is tied to the development of neurologic and psychiatric disorders (Beaulieu, Gainetdinov 
et al. 2009).   
The evidence linking an Akt loss of function to development of both IR and 
neuropsychiatric disease stems from a constellation of findings at genetic, animal model, 
neuroimaging, and post-mortem levels.  Genetic findings, regarding loss of function mutations in 
the isoform Akt2, supports that monogenic dysfunction in Akt signaling is sufficient to cause IR  
in both animal models and even rare patients (Cho, Mu et al. 2001; George, Rochford et al. 
2004).  Intriguingly, post-mortem studies in neuropsychiatric patients suggests that an Akt 
signaling loss of function, at the level of decreased expression and/or phosphorylation, is 
associated with depression, schizophrenia, and Parkinson’s disease (Emamian, Hall et al. 2004; 
Karege, Perroud et al. 2007; Timmons, Coakley et al. 2009).  Indeed, while a loss of function in 
Akt signaling is therefore a potential causative factor for both IR and neuropsychiatric disease, 
common treatments for both classes of disorders, including insulin, mood stabilizers, and 
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Figure 1.  The insulin/Akt signaling pathway. 
 
 
Schematic of the insulin/Akt signaling pathway.  Insulin activates Akt signaling by triggering its 
phosphorylation at the Threonine-308 and Serine-473 residues.  The surface receptor for insulin is 
an RTK that stimulates PI3K signaling after binding of its respective ligand.  Once activated, 
PI3K catalyzes the conversion of PIP2 to PIP3, which causes the translocation of Akt from the 
cytosol to the cell surface.  At the cell surface, Akt can be activated through phosophorylation by 
the kinases PDK1 and mTORC2, a multi-subunit signaling complex that depends on multiple 
proteins, including SIN1 and Rictor, to function.  Once activated, Akt exerts a diverse array of 
effects, including regulation of growth, proliferation, and transporter function.  Akt is regulated by 
numerous upstream factors in addition to insulin, such as other RTKs and neurotransmitter 
receptors, and in turn regulates diverse downstream signals.   Image courtesy of Dr. Aurelio Galli. 
 
antipsychotics, are also potent Akt stimulators (De Sarno, Li et al. 2002; Beaulieu, Sotnikova et 
al. 2004; Krishnan, Han et al. 2008; Asano, Fujishiro et al. 2007).   Thus, a preliminary 
framework suggests that a loss of function of Akt leads to the development of brain disorders, 
and stimulation of Akt leads to its treatment.  Therefore, Akt signaling dysfunction has high 
yield in terms of dissecting the relationships between IR and neuropsychiatric disease. 
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Insulin resistance, Akt signaling, and schizophrenia 
 
The disorder with the strongest evidence to support links between IR, Akt signaling, and 
dysfunctional neurotransmission is schizophrenia.  Schizophrenia and Type II diabetes, as 
addressed earlier, are frequently comorbid conditions, a finding generally attributed to the side 
effects of antipsychotic medications (Lebovitz 2001).  While the effects of the atypical 
antipsychotics on weight gain and diabetes risk are undeniable, compelling evidence suggests 
that impairments in glucose metabolism may be associated with the underlying disease process 
itself (Ryan, Collins et al. 2003; Venkatasubramanian, Chittiprol et al. 2007; Verma, 
Subramaniam et al. 2009).   A recent age- and sex-matched study, for example, demonstrates 
impaired fasting glucose tolerance in 15% of patients with new-onset, first episode 
schizophrenia, compared with 0% of controls (Ryan, Collins et al. 2003).  Later studies built on 
these findings, not only reproducing the observation of glucose intolerance in first episode 
patients, but building on them to demonstrate increased IR rates in the first degree relatives of 
probands compared to individuals with no psychiatric history (Spelman, Walsh et al. 2007).  This 
evidence suggests not only that IR is present in first episode patients with schizophrenia, but that 
this IR observed in patient populations has a genetic basis.   
While there therefore appears to be strong evidence for IR even in first episode psychotic 
patients, the body of work linking Akt to schizophrenia evolved separately from Akt’s role as an 
insulin effector.  In terms of the study of schizophrenia, Akt has value as a candidate gene, a 
biomarker, a therapeutic target, and a molecular component for building pathogenic models.  The 
breakthrough study regarding the role of Akt in schizophrenia was first published by Emamian 
and colleagues.  Guided by a hypothesis regarding the role of Akt as a synaptic plasticity protein, 
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Emamian et al. analyzed lymphocytes derived from control and patient populations at a 
biochemical level, identifying decreased expression of the isoform Akt1 in lymphocyte cell lines 
derived from patient populations.  This effect was additionally true in post-mortem brain, as they 
found decreased expression of Akt1 in cortical and hippocampal brain regions of schizophrenia 
patients (Emamian, Hall et al. 2004).  Emamian et al. then validated the biologic plausibility of 
their findings, using a murine model to directly probe how a loss of Akt signaling influences 
experimental phenotypes of schizophrenia.  To do so, they examined a reflex called sensorimotor 
gating in Akt1 null mice.  Sensorimotor gating is considered a cross-species endophenotype of 
schizophrenia that has a strong genetic influence.  Sensorimotor gating deficits are observed  in 
putative animal models of schizophrenia, patients with schizophrenia, and their first degree 
relatives (Braff, Geyer et al. 2001; Perry, Minassian et al. 2001; Swerdlow, Geyer et al. 2001; 
Powell, Zhou et al. 2009).  In murine models, sensorimotor gating is assessed through a task 
called prepulse inhibition (PPI) of the acoustic startle response.  Intriguingly, PPI assessments of 
Akt1 nulls demonstrate normal sensorimotor gating at baseline, but increased sensitivity to 
disruption with the indirect dopamine agonist amphetamine (AMPH), as opposed to the PCP-
derivative phencyclidine (Emamian, Hall et al. 2004).  This suggests that dopaminergic systems, 
as opposed to glutamatergic systems, are particularly susceptible to disruption in an Akt-
deficient state. 
Lastly, Emamian and colleagues looked at how treatment of schizophrenia affects Akt 
signaling.  Utilizing animal models, they demonstrated that the antipsychotic medication 
haloperidol increases the T308 and S473 phosphorylation of Akt (Emamian, Hall et al. 2004).  
From this study, Emamian therefore developed the initial framework to understand the links 
between Akt and schizophrenia.  They suggested, using convergent evidence across species, that 
 8 
loss of function in Akt is associated with development of schizophrenia, and gains of function in 
Akt signaling are associated with its treatment.   
 
Serine-473 phosphorylation of Akt and schizophrenia 
 
 In the years since publication of the study by Emamian et al, several studies expanded on 
the role of Akt, and the S473 phosphorylation site, in particular, as a potential biomarker for 
schizophrenia (Kéri, Seres et al. 2009; Keri, Beniczky et al. 2010; Kéri, Seres et al. 2011).  Due 
to its intracellular nature, and the difficulties with assessment of S473 in post-mortem tissue 
(Zhao, Ksiezak-Reding et al. 2006), phosphorylation studies of Akt are frequently performed 
using cultured lymphoblasts.  While there are many differences between lymphoblasts and 
neurons, they are a system that allows for assessment of intracellular signaling pathways directly 
in patient populations without significant confounds.   Indeed, in terms of a cellular migration 
phenotype, lymphoblasts are similar to cultured neurons in that both cell types will migrate 
toward the source of a neurotrophic ligand like neuregulin (NRG) (Sei, Ren-Patterson et al. 
2007).   
In the study of schizophrenia, both baseline and stimulated studies of lymphoblasts are 
performed, generally using an agonist like neuregulin, and biochemical findings are frequently 
correlated to additional experimental results.  For example, one such study from lymphoblasts 
analyzed how NRG affects S473 phosphorylation in normal volunteers and unmedicated, first-
episode patients.  In patients with schizophrenia, Sei et al. demonstrated impaired NRG-
stimulated S473 phosphorylation and cell migration compared to controls (Sei, Ren-Patterson et 
al. 2007).  Intriguingly, NRG-1 is itself a schizophrenia candidate gene (Harrison and 
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Weinberger 2004), and activates Akt in an RTK/PI3K-dependent manner, similar to the 
RTK/PI3K-dependent effects of insulin (Kanakry, Li et al. 2007).  The blunted Akt activation 
and cell migration observed in the study by Sei et al., therefore, suggests that defective 
machinery underlying Akt activation is present in patients with schizophrenia. 
Subsequent studies strengthen the relationship between a blunted activation of Akt, 
schizophrenia itself or schizophrenia-associated phenotypes.  For example, Keri et al. expand on 
the link between Akt signaling and brain function through correlation of Akt signaling in 
lymphocyte cell lines to personality assessments of the normal population.  Intriguingly, Keri et 
al. demonstrated that NRG-1 dependent stimulation of S473 inversely correlates with measures 
of delusionality.  The inverse relationship between Akt signaling and measures of delusionality 
therefore suggests that Akt signaling impairments, in individuals with no psychiatric history, 
leads to a psychosis-prone personality and, potentially, sensitivity to mental illness (Kéri, Seres 
et al. 2011). 
While the link between an Akt signaling deficit and a delusional personality is the first 
finding of its kind, Keri et al expanded on their findings to demonstrate how defects in Akt 
signaling affect psychophysical variables in schizophrenia patients.  To do so, Keri et al. 
repeated their biochemical analysis of Akt signaling in lymphocytes derived from patient 
populations, but this time coupled their findings to analysis of the P50 evoked sensory potential 
assay (Keri, Beniczky et al. 2010).  This test is performed by measuring electroencephalographic 
and electrooculographic responses to a pair of auditory stimuli presented in quick succession.  In  
healthy populations, the brainwave responses to the second stimuli are less than the brainwave 
responses to the first, a phenomenon called sensory gating (Keri, Beniczky et al. 2010).  Sensory 
gating phenotypes are very similar to sensorimotor gating phenotypes, in that individuals with 
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schizophrenia, and their first degree relatives, have impairments in sensory gating, suggesting it 
is a genetically-influenced reflex and potential endophenotype of schizophrenia (Siegel, Waldo 
et al. 1984).  Keri et al.’s analysis revealed not only that schizophrenia patients have impaired 
sensory gating compared to controls, but that these deficits also correlate with impairments in 
activation of Akt at the S473 residue (Keri, Beniczky et al. 2010).  Intriguingly, given the 
AMPH-induced impairments in sensorimotor gating observed in Akt1 null mice (Emamian, Hall 
et al. 2004; Keri, Beniczky et al. 2010), the association between Akt and psychophysical 
phenotypes of schizophrenia appears to extend across species.     
Despite the strength of the association between Akt and schizophrenia across species, the 
mechanisms underlying this association remain incompletely understood.  Indeed, Akt is a major 
cellular regulatory pathway that has diverse molecular effects.  The promiscuous regulatory 
potential of Akt makes it difficult to precisely identify how Akt influences the risk for 
schizophrenia.  However, understanding such mechanisms has the potential to yield therapeutic 
insights, as our current understandings of the mechanisms underlying schizophrenia itself are 
somewhat limited.  Indeed, our understanding of schizophrenia is based, to a significant extent, 
off our understanding of the neurocircuity and pharmacology that influences its symptomatology.  
Therefore, to help elucidate the underlying molecular mechanisms, the neurocircuits that appear 
to be particularly sensitive to disruption by both IR and Akt will be addressed in the following 
section. 
 
Akt, the prefrontal cortex, and dopamine 
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In addition to evidence supporting Akt as a biomarker of schizophrenia, emerging evidence 
suggests that the function of prefrontal cortical circuits, specifically prefrontal dopamine (DA), 
are particularly susceptible to disruptions in  insulin/Akt signaling.  Neuroimaging studies help to 
identify, at a structural and functional level, the effects of metabolic signaling disruptions on 
brain function.  For example, children with IR demonstrate reductions in prefrontal and 
hippocampal brain volumes (Bruehl, Sweat et al. 2011; Yates, Sweat et al. 2012).  In a similar 
fashion, genetic variation in Akt influences not only the size of prefrontal cortical structures, but 
also verbal learning and memory performance (Pietiläinen, Paunio et al. 2009).  Post-mortem 
studies of both depressed and schizophrenia patients augments the importance of insulin/Akt 
signaling pathways in prefrontal cortical regions, with separate cohorts demonstrating deficits in 
either phosphorylated Akt or Akt expression in patients with both major depression and 
schizophrenia (Karege, Perroud et al. 2007; Dwivedi, Rizavi et al. 2010).    
In addition to morphologic and post-mortem findings, recent investigations continue to 
develop the link between Akt and prefrontal cortex at genetic, biochemical, and functional levels.  
In one recent study, Tan and colleagues collected lymphocytes from normal volunteers, finding 
decreased expression of the Akt1 protein in individuals with Akt risk haplotypes for 
schizophrenia.  Additionally, Tan and colleagues used functional magnetic resonance imaging 
(fMRI) to assess the effects of Akt genetic variation on cortical networks during a working 
memory task.  They found that individuals with these “hypoactive” Akt1 alleles demonstrate 
impaired efficiency in the function of prefrontal networks, a phenotype also observed in the 
schizophrenia population (Tan, Nicodemus et al. 2008).  Separate neuroimaging cohorts re-
capitulate not only the association between Akt signaling and prefrontal cortical function, but 
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also suggest the penetrance of Akt risk alleles on PFC function increases in the presence of other 
schizophrenia candidate genes (Nicodemus, Law et al. 2010; Tan, Chen et al. 2012).   
Given that working memory tasks in prefrontal cortex are linked to the function of 
dopamine systems (Weinberger and Berman 1988), a “hypofrontality” of prefrontal DA systems 
is therefore hypothesized to result from impairments in Akt signaling.  The sensitivity of both 
working memory function and DA systems to disruptions in Akt-signaling is reflected by 
findings from animal models.  Behavioral analysis of mice lacking the isoform Akt1, for 
example, demonstrate that, under baseline conditions, Akt1 nulls are capable of normal 
acquisition of a working memory task called the delayed T-maze task.  However, Akt1 nulls, 
compared to their wild type counterparts, are more sensitive to working memory disruption in 
response to quinpirole and guanfacine, agents that challenge dopaminergic and noradrenergic 
systems, respectively (Emamian, Hall et al. 2004; Lai, Xu et al. 2006).  The NE disruption 
observed in Akt1 nulls is particularly intriguing, given the role of NE in PFC function, and CSF 
findings of NE alterations in patients with schizophrenia (Finlay, Zigmond et al. 1995; Friedman, 
Adler et al. 1999; Aston-Jones and Cohen 2005).   
Therefore, although Akt is a kinase whose dysfunction is likely to affect multiple tissue 
types, brain regions, and molecular systems, neuroimaging findings support that PFC networks 
are particularly prone to Akt signaling disruptions.  Additionally, while a loss of function in Akt 
is likely to impact multiple neurotransmitter systems, many of the functions that are impaired in 
these neuroimaging studies are particularly dependent on prefrontal DA networks.  , Animal 
models corroborate neuroimaging findings, as pharmacologic studies in animals lacking the 
isoform Akt1 suggests that working memory performance is sensitive to disruption in response 
to both  DA and NE challenge.  Collectively, therefore, evidence across species suggests that 
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catecholamine systems, particularly DA systems in the prefrontal cortex, are critical components 
of the association between Akt and the central nervous system. 
 
Overview of dopamine and norepinephrine systems in brain 
 
In order to understand the links between IR, Akt signaling, and the catecholamines, it is helpful 
to first review relevant catecholamine neuroanatomy.  DA and norepinephrine (NE) are the two 
major catecholamines in brain.  There are four major DA projections in brain- the mesolimbic, 
mesofrontal, mesostriatal, and tuberoinfundibular.  The mesolimbic, mesofrontal, and 
mesostriatal projections are those most frequently studied in the context of neuropsychiatric 
disease.  The cell bodies for these projections lie in the midbrain, specifically the ventral 
tegmental area (VTA) and substantia nigra (SN) (Dunnett, Björklund et al. 2005).  The distal 
axonal projections of these circuits lie in the prefrontal cortex, nucleus accumbens, and dorsal 
striatum, respectively.  The three separate functions of reward, cognition, and locomotion are 
frequently ascribed to DA projections in brain.  While an oversimplification of a complex 
system, the mesofrontal circuit is most tightly linked to cognition, the mesolimbic circuit to 
reward, and the mesostriatal system to locomotion (Dunnett, Björklund et al. 2005).   
Unlike the relatively restricted projections of the dopaminergic system, NE neurons 
innervate virtually all areas of the brain including the spinal cord.  Indeed, a single noradrenergic 
neuron can innervate regions as disparate as the cortex and spinal cord (Room, Postema et al. 
1981).  The noradrenergic system is subdivided into two major divisions, the lateral tegmental 
(LT) system and the locus coeruleus (LC). The LT system, which is substantially less well 
studied than the LC, projects primarily to the spinal cord, brainstem, hypothalamus, and basal 
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forebrain (Moore and Bloom 1979).  The LC, in contrast, both receives information from 
numerous brain regions and subsequently projects to a wide array of regions, providing a 
potential point of convergence between disparate streams of information (Simpson, Altman et al. 
1997).  As reflected in these projections, the LC noradrenergic system plays important roles in 
the regulation of food intake, stress, anxiety, and sympathetic nervous system activation.  
Disruption in both DA and NE systems, therefore, and pharmacological targeting of these same 
systems, are key components of the pathogenesis and treatment of many neuropsychiatric 
disorders.  A summary of DA and NE projections in the brain are depicted in Fig. 2. 
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Figure 2.  Dopaminergic and noradrenergic pathways in brain. 
 
 
Diagram of dopaminergic (top) and noradrenergic projections (bottom) in brain. The 
mesocortical DA neurons, which originate in the VTA and project to the medial/frontal 
lobes of cortex, and mesostriatal DA neurons, which originate in SN and project to the 
dorsal striatum, are depicted. The more diffuse pattern of NE innervation can be 
appreciated, in contrast.  Co-innervation of DA and NE fibers of cortical regions can be 
appreciated in this image. Image adapted from Neuroscience Exploring the brain Third 
Edition by Mark F. Barry, Barry Connor, and Mark. F. Paradiso. 
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Dopaminergic and noradrenergic networks in schizophrenia 
 
Of the four dopaminergic pathways in brain, the mesostriatal and mesocortical systems 
are the best characterized in terms of neuropsychiatric disease.  Mesostriatal DA circuits are 
hypothesized to underlie the movement symptoms of Parkinson’s disease and the positive 
symptoms of schizophrenia.  In the context of Parkinson’s disease, post-mortem findings suggest 
that a loss of mesostriatal DA precipitates the onset of movement symptoms in this disorder 
(Kish, Shannak et al. 1992).  Conversely, enhanced release of DA from mesostriatal DA neurons 
are associated with the positive symptoms of schizophrenia (Howes and Kapur 2009).  The 
evidence supporting an increased DA release in schizophrenia is based off of separate, indirect 
lines of evidence.  One key clinical finding supporting an enhanced release of striatal DA in 
schizophrenia depends on the fact that the effective dose of antipsychotic medications correlates 
with their ability to antagonize the DA D2 receptor (Creese, Burt et al. 1976; Snyder 1976).  A 
second piece of evidence centers on historical reports describing how high doses of AMPHs – 
drugs that trigger the extracellular release of catecholamines like DA – produce a psychotic state 
clinically indistinguishable from schizophrenia (Snyder 1973).   Another critical piece of 
evidence is derived from data produced by the advent of positron emission tomography (PET) in 
the 1990’s.  This data demonstrates that, in patients with schizophrenia compared to controls, 
there is increased displacement of a DA-receptor ligand in the striatum after AMPH 
administration.  The authors use this increased displacement of DA receptors as an indirect 
indicator of increased striatal dopaminergic transmission.  This triad of evidence, demonstrating 
AMPH-induced psychosis, ability of  antipsychotics to antagonize the D2 receptor, and increased 
striatal DA release after AMPH administration, formed a cornerstone for understanding the 
 17 
treatment and pathogenesis of schizophrenia for decades (Laruelle, Abi-Dargham et al. 1999; 
Howes and Kapur 2009). 
While increased release of mesostriatal DA is hypothesized to underlie the positive 
symptoms of schizophrenia, additional evidence suggests that mesofrontal DA circuitry is 
differentially impaired.  Mesofrontal circuits are hypothesized to underlie the negative and 
cognitive symptoms of schizophrenia (Howes and Kapur 2009).  At a neurochemical level, the 
basis between DA and the function of prefrontal cortical networks is best established in a 
landmark study by Weinberger et al.  Utilizing functional imaging techniques coupled with 
neurochemical assessment of the cerebrospinal fluid (CSF), Weinberger et al. demonstrated not 
only that prefrontal activation during cognitive tasks was impaired in patients with 
schizophrenia, but that this impairment correlates with reductions of the DA metabolite 
homovanillic acid (HVA) in the CSF (Weinberger Dr 1988). This led to the reconceptualization 
of the DA hypothesis of schizophrenia, to suggest that, while a DA exaggeration in striatal brain 
regions underlies the positive symptoms of the disease, a DA deficit, present in prefrontal cortex, 
underlies the negative and cognitive symptoms of disease (Weinberger Dr 1988).  As these 
symptoms are a significant cause of the disability associated with the diagnosis (Hafner, Löffler 
et al. 1999; Niendam, Bearden et al. 2006; Leifker, Bowie et al. 2009), much attention, in recent 
years, focuses on cortical DA dysfunction as a means to treat cognitive dysfunction.   
 It is important to note that complex neurotransmitter systems, in addition to DA, are 
found to be abnormally regulated in schizophrenia.  Indeed, strong evidence supports a role for 
NE dysfunction.  In the 1980’s, for example, CSF studies of patients with schizophrenia 
demonstrate consistent and reproducible elevations of NE in patients compared to controls.  
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Cerebrospinal elevations in NE levels led to the evolution of hypotheses regarding a basis for 
noradrenaline in schizophrenia (Hornykiewicz 1982).   
In addition to a potential role in manifestation of schizophrenia, NE is also a critical 
regulator of prefrontal cortex function.  For example, animal models demonstrate that NE release 
in the PFC is important for the maintenance of attention and ultimately memory (Abercrombie 
and Jacobs 1988; Aston-Jones, Rajkowski et al. 1999; Usher, Cohen et al. 1999; Aston-Jones and 
Cohen 2005).  Additional evidence suggests that NE release, particularly in the PFC, correlates 
with the amount of arousal of an organism experiences and its response to stress (Aston-Jones 
and Bloom 1981; Nakane, Shimizu et al. 1994; Finlay, Zigmond et al. 1995).  Given that 
attention and the stress response are two symptom dimensions altered in schizophrenia, 
noradrenergic agents remain an attractive pathway for development of neuropsychiatric 
therapeutics (Arnsten 2004).  
 Therefore, clinical and animal model evidence, to this point, suggests that disruptions in 
Akt signaling profoundly affects the function of prefrontal cortex systems, potentially due to its 
effects on DA and NE systems.  Intriguingly, Akt, DA, and NE systems are all disrupted in 
schizophrenia, and promising targets for the treatment of neuropsychiatric disease in general.  
However, the mechanistic links underlying the relationships between Akt, DA, and NE systems 
remain only partially understood.  Therefore, the impact of Akt signaling on DA and NE 
systems, at cellular and molecular levels, will be addressed in subsequent sections. 
 
 19 
Figure 3.  Regulation of synaptic monoamines. 
 
 
Schematic depicting the mechanisms underlying regulation of the major monoamine 
neurotransmitters in brain, namely DA, NE, and 5-hydroxytryptamine (5HT, commonly 
known as serotonin).  The monoamines share in common aromatic amino acid precursors, 
namely tyrosine for the DA and NE systems, and tryptophan for 5HT. 5HT neurons are 
included as a reference, given similarities between the regulation and pharmacology of all 
monoamines, but DA and NE neurons are the focus of this thesis.  TH catalyzes the formation 
of DA from tyrosine, which is in turn metabolized into NE by dopamine beta hydroxylase 
(DBH) in NE neurons.  The packaging of transmitter into vesicles, release into the synaptic 
cleft following presynaptic stimulation, diffusion into the synaptic cleft, stimulation of pre- 
and post-synaptic receptors, and uptake by pre-synaptic transporters are all depicted for the 
respective neurons.  Transport mechanisms can be targeted by diverse pharmacological 
agents, depicted above.  Adapted from Torres et al., 2003.   
 
 Dopamine neuron survival and Akt 
 
Given the classical role of Akt as an oncoprotein, and its associated role in determining cellular 
growth and survival (Testa and Bellacosa 1997; Manning and Cantley 2007; Cicenas 2008; Kim, 
Duan et al. 2009; Mairet-Coello, Tury et al. 2009), one important mechanism to consider when 
evaluating the role of Akt on the function of DA systems is the survival of DA neurons.  The 
effects of DA neuron cell death can be modeled through administration of the neurotoxic DA 
analogue 6-hydroxydopamine (6-OHDA), an agent capable of destroying both dopaminergic and 
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noraderenergic nuclei in the brain (Jeste and Smith 1980; Bing, Zhang et al. 1994).  In line with 
causing reductions in DA neuron cell number after administration of neurotoxic agents, there are 
neurochemical reductions in total DA levels following administration of 6-OHDA (Fink and 
Smith 1979).  DA neurotoxic agents, in turn, cause characteristic behavioral effects.  For 
example, in the assessment of open field behavior, 6-OHDA-treated animals show diminished 
exploratory locomotion (Fink and Smith 1979).  As these open field exploratory deficits are 
ameliorated by DA repletion (Fink and Smith 1979), this suggests that DA depletion is sufficient 
to cause reductions in locomotor activity.   
In addition to the effects of DA depletion on striatal DA systems and dependent 
behaviors, DA neurotoxins like 6-OHDA also affect the function of cortical catecholamine 
systems.  For example,  6-OHDA lesions directed specifically at the medial forebrain bundle, 
which connects ventral tegmental DA neurons to their projections in the prefrontal cortex, cause 
deficits in sensorimotor gating behaviors that correlate with reductions in cortical DA levels 
(Bubser and Koch 1994; Koch and Bubser 1994; Swerdlow, Shoemaker et al. 2006).   
Therefore, the potential effect of Akt on neuronal survival is an important mechanism to 
consider when analyzing the impact of insulin/Akt signaling on neuropsychiatric disease.  
Indeed, the role of insulin/Akt pathways in neuronal growth and survival dates back, to a certain 
extent, to classic studies by Stanley Cohen and Rita Levi-Montalcini in the 1950s.  Cohen and 
Levi-Montalcini demonstrated, in chick embryos, that isolation and administration of the ligand 
nerve growth factor (NGF) promotes neurite outgrowth (Cohen, Levi-Montalcini et al. 1954; 
Cohen and Levi-Montalcini 1956; Cohen and Levi-Montalcini 1957).  Subsequent evidence 
determines that NGF exerts its effects, in part, through an RTK/PI3K dependent manner in 
dopaminergic cell lines (Kim, Seger et al. 2004).  Indeed, other stimulators of RTK signaling 
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cascades, like insulin-like growth factor (IGF), affect neuronal migration, cellular growth, and 
survival of dopaminergic neurons in an analogous manner to NGF (Bogush, Pedrini et al. 2007; 
Sei, Ren-Patterson et al. 2007; Altar, Hunt et al. 2008).  The pro-survival effect of IGF appears to 
be PI3K dependent, as the PI3K inhibitor LY294002 attenuates the ability of IGF-1 to stimulate 
growth cone expansion in cultured neurons (Laurino, Wang et al. 2005).     
Therefore, stimulation of RTK/PI3K signaling networks promotes DA neuron growth and 
survival, and inhibition of RTK/PI3K signaling interferes with these processes.  In line with the 
ability of RTK/PI3K signaling to regulate Akt, transgenic mice with gains and loss of function in 
Akt signaling, respectively, recapitulate the effects of RTK agonism and PI3K inhibition on cell 
growth, survival, and neuronal migration.  For example, a loss of the isoform Akt3 leads to 
prominent (~25%), symmetric reductions in rodent brain size, an effect driven by reductions in 
both neuron size and number.  This reduction in brain size in Akt3 nulls is consistent with effects 
of PI3K inhibition on neuronal outgrowth and survival observed in cellular models (Yang, 
Tschopp et al. 2004; Easton, Cho et al. 2005).  Additionally, Parkinson mimetics like 6-OHDA 
upregulate proteins that are potent inhibitors of Akt signaling, a finding which suggests that Akt 
signaling impairments underlie cell death in Parkinson’s disease (Malagelada, Jin et al. 2008). 
In contrast to a loss of Akt signaling impairing growth and survival of DA neurons, 
opposing cellular phenotypes are observed with gains of function in Akt.  One such model is a 
transgenic mutant with neuronal loss of function in PTEN (phosphatase and tensin homolog).  
PTEN is a tumor suppressor protein that acts as a negative regulator of Akt, interfering with its 
function.  PTEN-deficient mice, therefore, leads to gains of function in Akt signaling, and 
subsequent enhancements in brain size at 10 weeks of age (Backman, Stambolic et al. 2001).  
Similar effects are observed when deletion of PTEN is restricted to dopaminergic cells, as 
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animals lacking PTEN in DAT neurons show increases in midbrain DA neurons and striatal 
markers of DA synapses (Diaz-Ruiz, Zapata et al. 2009), suggesting that gains of function in Akt 
serve to promote the cellular growth of dopaminergic systems.   
The development of viral vectors encoding specific components of Akt signaling 
cascades reinforce the overall role of Akt on neuronal growth and survival.  The effects of 
genetic Akt manipulation on neuronal survival can be best studied following injection of viral 
vectors into either the SN or VTA, where DA neuron cell bodies resides.  Inhibition of Akt 
signaling in DA neurons, for example, as accomplished via injection of vectors encoding 
dominant negative insulin receptor substrates (dnIRS), reduces both DA neuron cell size and Akt 
phosphorylation (Russo, Bolanos et al. 2007).  Viruses encoding dominant negative forms of Akt 
(dnAkt) have similar effects to dnIRS, as dnAkt viruses injected directly into the midbrain 
reduces DA neurons cell number and size.  Additionally, dnAkt viruses also limit the extent of 
dorsal striatum innervation, where DA neurons project (Ries, Cheng et al. 2009). 
In contrast to the effects of viral interference of Akt signaling, viral enhancement of Akt 
signaling can also be achieved.  One strategy to enhance Akt signaling involves the engineering 
of viruses that express Akt proteins with myristoylated moieties (myrAkt), resulting in 
constitutive activation of this protein by promoting its trafficking to the cell surface.  MyrAkt 
treatments, in stark contrast to dnAKT treatments, increase TH neuron density in the SN, target 
innervations of the striatum, and, importantly, total DA levels in the midbrain (Ries, Henchcliffe 
et al. 2006; Ries, Cheng et al. 2009).  In addition to its role in the promotion of neuronal survival 
and target innervation, animals receiving injections of the DA neurotoxin 6-hydroxydopamine 
(6-OHDA), following myrAkt pretreatment, show reductions in the extent of DA lesioning.  
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Together, this evidence suggests that a loss of Akt function interferes with DA neuron survival, 
and gains of function in Akt exerts prominent protective effect on DA neurons.  
 
Akt and dopamine synthesis 
 
Tyrosine hydroxylase is the rate-limiting protein responsible for catecholamine biosynthesis.  It 
is expressed in the central and peripheral nervous system, including adrenal chromaffin cells.  
The function of TH is tightly regulated through transcriptional and post-translational 
mechanisms, including protein phosphorylation. The effects of TH function at a behavioral level 
can be understood through pharmacologic and genetic interference with protein function.  TH 
can be inhibited with alpha-methyl-tyrosine (APMT), an agent classically used as an 
antipsychotic and antihypertensive agent.  APMT administration causes reductions in CNS 
catecholamines and locomotor activity in mice (Jeste and Smith 1980), analogous to the effects 
of DA neurotoxins on locomotor behavior .  Therefore, while it is clear from the previous section 
that Akt has an effect on the growth and survival of DA neurons, mechanisms like tyrosine 
hydroxylase function may also explain the influence of Akt on the function of DA systems.       
In the 1990’s Richard Palmiter and colleagues generated a series of knockout (KO) mice, 
targeting the catecholamine synthetic pathway through TH deletion, in order to better evaluate 
the effects of TH (TH-KO) (Thomas, Matsumoto et al. 1995; Zhou and Palmiter 1995; Zhou, 
Quaife et al. 1995).  Interestingly, TH-KO proved to be embryonic lethal, emphasizing the 
importance of the catecholamines (Thomas, Matsumoto et al. 1995), as a group, for 
embryogenesis.  In later years, Dr. Palmiter was eventually able to construct a TH-KO model 
where TH was restored in cells co-expressing DBH, leading to the generation of what were 
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termed DA-deficient mice (Zhou and Palmiter 1995).  These mice show normal levels of NE and 
epinephrine (EPI), and survive past birth (Zhou and Palmiter 1995).  However they also show 
marked reductions in brain DA content, similar to that observed in mice with 6-OHDA lesions.  
Remarkably, these mice show similar behavioral phenotypes as 6-OHDA models, and are 
profoundly hypokinetic in the open field (Zhou and Palmiter 1995).  In fact, their hypokinesia is 
so profound that it is described as a total amotivational state.  Their hypokinesia is so severe that 
is leads to a near complete lack of self-care, and without intervention, DA-deficient mice die 
within seven days of birth (Zhou and Palmiter 1995).   This amotivational state is attributed to a 
complete lack of extracellular DA in DA-deficient mice, leading to a subsequent lack of 
exploratory activity and locomotor response to AMPH.  These behaviors, however, are restored 
when DA levels are restored through pharmacologic (Szczypka, Rainey et al. 1999) or genetic 
methods (Heusner, Hnasko et al. 2003; Palmiter 2008).   
While there is no evidence, to date, to suggest that Akt directly affects the function of TH 
at either a transcriptional or post-translational level, there is evidence to suggest that signals 
upstream of Akt enhance pre-synaptic function of DA neurons, potentially via a TH-dependent 
mechanism.  For example, many growth factors, including NGF, EGF, and IGF-1, enhance the 
release of DA in pheochromocytoma (PC12) cells, a cultured cell line that expresses all the 
necessary machinery for synthesis and release of DA.   Intriguingly, the ability of these growth 
factors to enhance the release of DA from PC12 cells is subject to inhibition of PI3K (Amino, 
Itakura et al. 2002; Itakura, Yamamori et al. 2005) .  Recent evidence implicates that this effect 
is true in brain also, as treatment with BDNF in striatal slice preparations enhances DA release in 
a manner blocked by the PI3K inhibitor LY249002 (Goggi, Pullar et al. 2003).     
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While the effects of RTK/PI3K on the enhancement of presynaptic DA release, therefore, 
appears to be reproducible by different groups, a dependence of this effect on TH has yet to be 
revealed.  Indeed, while some RTKs appear able to modulate TH activity, this effect may be 
dependent on RTK effectors that are activated in parallel to Akt, and not Akt itself. For example, 
one study, focused on the effects of fibroblast growth factor (FGF), an RTK ligand linked to 
Parkinson’s disease, demonstrates that FGF administration does indeed increase TH activity 
(Murase and McKay 2006).  However, the downstream mediators of the FGF effect appear to be 
driven by the MAPK cascade, and not signaling through PI3K/Akt (Murase and McKay 2006).  
Thus, current findings do not support a direct effect of Akt on TH, although a broad body of 
evidence, addressed in the previous section, supports a role for Akt in the growth and survival of 
TH neurons. 
 
Akt and the dopamine transporter 
 
In addition to deficiencies in the total number or survival of DA neurons, and beyond control of 
DA synthesis, another critical mechanism that regulates the function of DA systems is the DA 
transporter (DAT).  DAT allows DA to be cleared out of the synapse and taken up into the 
presynaptic bouton.  Therefore, DAT is a critical protein for regulation of synaptic DA levels and 
the recycling of DA from the extracellular space.  Interference with the DAT interferes with both 
of these functions (S.P 1995).  Consistent with genetic interference in the ability to recycle 
released DA, mice lacking the DAT (DAT-KO) mice show marked reductions in total DA levels.  
In fact, the striata of DAT-KO mice contain only 5% the tissue content of their wild type 
counterparts (Giros, Jaber et al. 1996; Gainetdinov, Jones et al. 1999). This reduction in tissue 
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DA levels is of sufficient magnitude to resemble the DA-deficiencies observed in DA neurotoxin 
models.  However, despite this marked reduction in tissue DA levels, DAT-KO mice are 
markedly hyperactive in the open field, showing increases in exploratory behavior that are an 
order of magnitude greater than wild type controls.  Indeed, the increase in locomotor activity 
observed in DAT-KO mice is linked to adaptations, at the level of DA synthesis and autoreceptor 
downregulation, that creates fivefold elevations in extracellular DA, despite marked overall 
reduction in tissue DA  (Giros, Jaber et al. 1996; Gainetdinov, Jones et al. 1999).  Inhibition of 
TH, however, at a dose that causes minimal impairment in control animals, markedly interferes 
with both extracellular DA levels and locomotor activity in DAT-KO (Cyr, Beaulieu et al. 2003; 
Sotnikova, Caron et al. 2006).    
Based off the parallels between elevated synaptic DA levels in DAT-KO mice and 
elevations in striatal DA transmission observed in schizophrenia patients, DAT-KO mice are 
considered putative schizophrenia models (Howes and Kapur 2009).  In line with their role as a 
schizophrenia model, DAT-KO mice also demonstrate sensorimotor gating impairments.  As 
described earlier, these sensorimotor gating impairments are additionally found in patients with 
schizophrenia and their first degree relatives.  Intriguingly, sensorimotor gating deficits in DAT-
KO mice are corrected toward baseline with antipsychotic medications (Gainetdinov, Mohn et al. 
2001; Ralph, Paulus et al. 2001; Powell, Young et al. 2008; Powell, Zhou et al. 2009). 
Indeed, as an emerging body of evidence suggests that both IR and Akt signaling have 
profound effects on DAT function, DAT dysregulation is a potential mechanism to explain the 
role of IR in neuropsychiatric disease.  There is a broad base of knowledge, in fact, supporting 
RTK/PI3K signaling, in general, as a mechanism of DAT regulation.  For example, in rat striatal 
synaptosomes, both RTK inhibition and PI3K inhibition lead to decreases in DAT cell surface 
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expression, causing subsequent reductions in DA clearance rates (Hoover, Everett et al. 2007).  
Conversely, acute growth factor (BDNF) treatment increases DA uptake, in a manner that is 
prevented by co-treatment with the PI3K inhibitor LY294002 (Hoover, Everett et al. 2007).  
Additionally, FGF treatment of cultured dissociated DA neurons, which increases TH function, 
as described previously, also promotes DAT surface expression (Murase and McKay 2006). 
These in vitro and ex vivo findings, which suggest that that RTKs act via PI3K to increase 
DAT surface expression and function, are corroborated by in vivo models of insulin function and 
dysfunction.  The first model to demonstrate a link between insulin signaling cascades and DAT 
function is the streptozotocin (STZ) model, which demonstrates hypoinsulinemia secondary to 
beta cell destruction.  Consistent with the effects of insulin on Akt signaling, the STZ model is 
S473 deficient in striatal brain regions (Robertson, Matthies et al. 2010).   STZ-treated mice 
additionally show reductions in midbrain DAT mRNA (Figlewicz, Brot et al. 1996), and have 
reductions in striatal DAT surface expression (Williams, Owens et al. 2007).   This effect 
appears to be dependent on impairments in PI3K/Akt signaling, and not an effect of a confound 
of the model like inflammation, as direct treatment of striatal slices with the PI3K inhibitor 
LY294002, along with direct inhibition of Akt itself, additionally decrease cell surface 
expression of the DAT (Williams, Owens et al. 2007; Speed, Matthies et al. 2010).  In vivo 
evidence validates that Akt deficient states affect DA systems at a functional level.  Reductions 
in both DA clearance rates, and the amount of DA released following AMPH stimulation, are 
observed in both the STZ model and following PI3K inhibition.  Therefore, an Akt-deficient 
state, according to these models, impairs the ability of the DAT to both clear synaptic DA or 
release DA in response to AMPH stimulation (Williams, Owens et al. 2007).   
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In contrast to insulin/Akt signaling deficiencies causing an apparent impairment in DAT 
function, stimulation of Akt signaling appears to increase DAT function.  For example, chronic 
injections of insulin directly into the brain increase DAT mRNA expression in the VTA 
(Figlewicz, Szot et al. 1994).  Additionally, direct injections of insulin into the CNS, acutely, 
increases striatal DA clearance rates (Williams, Owens et al. 2007).   Intriguingly, DA release 
and DA clearance rates are rescued in the STZ model following direct injections of insulin into 
striatal brain regions, further suggesting that DAT deficits observed in this model are due to local 
neuronal signaling impairments (Williams, Owens et al. 2007),    
 
Akt and the norepinephrine transporter 
   
While it is therefore clear that Akt dysfunction is likely to impact DAT function, this effect may 
not be able to explain the effects of Akt on DA signaling in cortical brain regions.  Indeed, while 
DAT expression is high in striatal brain regions, its expression is low in the PFC.  Microdialysis 
studies confirm this suspicion, as prefrontal cortex DA clearance is insensitive to selective DAT-
inhibitors (Gresch, Sved et al. 1995; Yamamoto and Novotney 1998; Moron, Brockington et al. 
2002; Miner, Schroeter et al. 2003; Liprando, Miner et al. 2004).   
One mechanism to consider, therefore, when evaluating the effects of Akt on prefrontal 
regulation of DA, is via its influence on the NET.  Evidence supporting that Akt acts as a 
negative regulator of the NET stems from observations regarding the ability of insulin to 
decrease NE uptake in neuronal cultures, dissociated brain cells, and both hypothalamic and 
hippocampal slices.  Treatment of hippocampal slices and cultured sympathetic neurons reveals 
that the ability of insulin to decrease NE uptake depends on its ability to internalize the NET.  
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Additionally, co-treatment of hippocampal slices with both insulin and Akt inhibitors blocks the 
ability of insulin to decrease NET expression.  Lastly, the STZ-model has increased surface 
expression of the NET, increased total NE levels in the hippocampus, and increased NE 
clearance rates, all of which are normalized with insulin treatments (Robertson, Matthies et al. 
2010).  This evidence, suggests, collectively, that a loss of Akt signaling would, theoretically, 
lead to an upregulation of the NET. 
NET dysfunction, hypothetically, can have dramatic influence on the homeostasis of 
other monoamines, particularly DA in the cortical brain regions.  In fact, the NET has a higher 
affinity for DA than its nominal substrate in vitro (Xu, Gainetdinov et al. 2000).  Indeed, 
microdialysis studies suggest that NET reuptake of DA, in regions of low DAT expression such 
as the cortex, or even in regions with substantial DAT expression such as the shell of the nucleus 
accumbens, can significantly influence dopaminergic tone in the brain (Gresch, Sved et al. 1995; 
Yamamoto and Novotney 1998; Moron, Brockington et al. 2002; Miner, Schroeter et al. 2003; 
Liprando, Miner et al. 2004).  Mice lacking the NET (NET-KO), confirm the effects of NET 
disruption on DA systems, as NET-KO mice display disrupted DA clearance in the cortex and 
DA receptor supersensitivity, a phenomenon hypothesized to underlie their increased 
responsiveness to psychostimulants like AMPH and cocaine (Xu, Gainetdinov et al. 2000; 
Moron, Brockington et al. 2002; Keller, Diedrich et al. 2006). 
     
Introduction to the Rictor-nKO model 
 
Therefore, while a broad body of evidence suggests that dysfunction in Akt signaling 
influences the function of prefrontal cortical networks, and subsequent risk for neuropsychiatric 
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disease, the mechanisms underlying this association remain partly understood. Pharmacological 
evidence in Akt1 null mice demonstrate normal sensorimotor gating and working memory 
function, two endophenotypes of schizophrenia, at baseline, but enhanced sensitivity to 
disruption with dopaminergic and noradrenergic agents (Emamian, Hall et al. 2004; Lai, Xu et al. 
2006).  While these single transgene studies are particularly striking, and provide biologic 
validity to the clinical evidence linking Akt to mental illness, advances in transgenic technology 
allow greater molecular dissection into the mechanisms underlying mental illness.   
To date, is not yet known what the effects of the upstream kinases that activate Akt 
signaling, namely PDK1 and mTORC2, have on dopaminergic neurotransmission.  Part of that 
reason is genetic interference with these kinases, through constitutive  deletion of the PDK1 
enzyme, and Rictor, an mTORC2 subunit protein critical for the S473 phosphorylatoin of Akt, 
yield nonviable organisms (Shiota, Woo et al. 2006).  However, as these enzymes catalyze the 
T308 and S473 phosphorylation of Akt, and these steps are altered either in association with 
schizophrenia or by antipsychotic medications (Emamian, Hall et al. 2004; Kéri, Seres et al. 
2009; Keri, Beniczky et al. 2010; Kéri, Seres et al. 2011), a further understanding of these 
proteins in brain function may yield novel insights into neuropsychiatric disorders.   
The development of Cre-lox mediated genetic recombination technology allows the 
selective deletion of genes along tissue specific promoters, increasing our ability to study the 
effects of genes whose constitutive deletions are embryonically lethal.  Indeed, the Nestin-Cre 
promoter is an intriguing neuronal promoter to consider for initial studies, due to its ability to 
delete this gene in the entire brain.  This genetic strategy, driving the deletion of a gene of 
interest along a Nestin-Cre promoter, generates viable mice for the Rictor gene, but not for the 
PDK1 gene (Oishi, Watatani et al. 2009).   
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The Rictor/Nestin-Cre transgenic cross, therefore, will be the subject of the initial 
investigations of this model.  The specific aims of the thesis will focus on elaboration of pre-
synaptic mechanisms, including TH, DAT, and NET regulation, for the initial inquiry.  
Evaluation of post-synaptic hypothesis will be considered throughout, and specific experiments 
to evaluate post-synaptic mechanisms will be considered in the Future directions section. 
The specific aims, therefore, of this thesis are as follows: 
 
1.) Assess the effects of neuronal Rictor deletion behaviors which depend on the appropriate 
function of DA systems, including sensorimotor gating, open field locomotion, and the 
locomotor response to AMPH. 
2.) Assess the effects of neuronal Rictor deletion on cortical catecholamine systems, with 
particular emphasis of the effects of Rictor deletion on tissue catecholamine levels and 
transporter function.      
3.) Assess the effects of neuronal Rictor deletion on striatal DA catecholamine systems, and 
discuss preliminary data and potential post-synaptic mechanism underlying the effects of 
Rictor on striatal physiology. 
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CHAPTER II 
 
DYSREGULATION OF THE NOREPINEPHRINE TRANSPORTER SUSTAINS CORTICAL 
HYPODOPAMINERGIA AND SCHIZOPHRENIA-LIKE BEHAVIORS IN NEURONAL 
RICTOR NULL MICE 
Abstract 
 
Background:  The mammalian target of rapamycin (mTOR) complex 2 (mTORC2) is a 
multimeric signaling unit that phosphorylates protein kinase B/Akt following hormonal and 
growth factor stimulation.  Defective Akt phosphorylation at the mTORC2-catalyzed S473 site 
has been linked to schizophrenia.  While human imaging and animal studies implicate a 
fundamental role for Akt signaling in prefrontal dopaminergic networks, the molecular 
mechanisms linking Akt phosphorylation to specific schizophrenia-related neurotransmission 
abnormalities have not yet been described.  Importantly, current understanding of schizophrenia 
suggests that cortical decreases in DA neurotransmission and content defined here as cortical 
hypodopaminergia contribute to both the cognitive deficits and the negative symptoms 
characteristic of this disorder. We sought to identify a mechanism for how aberrant Akt signaling 
leads to these hallmarks of schizophrenia.  
Methodology/Findings:  We used conditional gene targeting in mice to eliminate the mTORC2 
regulatory protein rictor in neurons, leading to impairments in neuronal Akt S473 
phosphorylation.  Rictor-null (Rictor-nKO) mice show prepulse inhibition (PPI) deficits, a 
schizophrenia-associated behavior. In addition, they also show reduced prefrontal dopamine 
(DA) content, elevated cortical norepinephrine (NE), unaltered cortical serotonin (5-HT), and 
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enhanced expression of the NE transporter (NET). In the cortex, NET takes up both extracellular 
NE and DA. Importantly, in Rictor-nKO mice NET blockade reversed cortical deficits in DA and 
PPI deficits, suggesting that dysregulation of DA homeostasis is driven by alteration in NET 
expression which we show is ultimately influenced by Akt phosphorylation status.  
Conclusions/Significance:  These data illuminate a molecular link, Akt regulation of NET, 
between the recognized association of Akt signaling defects in schizophrenia with a specific 
mechanism for cortical hypodopaminergia and hypofunction. Additionally, our findings identify 
Akt as a novel modulator of monoamine homeostasis in the cortex. 
 
Introduction 
 
Mammalian target of rapamycin (mTOR) complex 2 (mTORC2) is one of two highly 
conserved protein kinases that are critical regulators of cell growth and metabolism.  mTOR 
complex 1 (mTORC1) and mTORC2 are functionally distinct multiprotein complexes that are 
defined by their subunit composition, rapamycin sensitivity, and substrate selectivity.  Raptor, 
mLST8, PRAS40, and mTOR comprise the rapamycin sensitive mTORC1 while the rapamycin 
insensitive mTORC2 contains rictor, mSIN1, mLST8, and mTOR.  Two key substrates of 
mTORC1 are S6K and 4E-BP, which are important regulators of translation, while protein 
kinase B, also known as Akt, is the primary substrate of mTORC2 (Sarbassov, Guertin et al. 
2005).  Specifically, mTORC2 is the kinase responsible for phosphorylation of Akt at serine 
residue 473, one of two key phosphorylation sites (Sarbassov, Guertin et al. 2005).  Akt is an 
extensively studied kinase that has been implicated in numerous disorders such as diabetes, 
obesity, cancer, and mental disorders such as schizophrenia (Beaulieu, Gainetdinov et al. 2009).  
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Post-mortem, imaging and genetic association studies in humans (Emamian, Hall et al. 2004; 
Dawn, Vladimir et al. 2008; Tan, Nicodemus et al. 2008) reveal that Akt deficiencies are 
associated with schizophrenia.  Genetic studies in rodents further corroborate the relationship 
between dysregulation in Akt signaling and disruptions in dopamine (DA)-associated behaviors 
linked to schizophrenia (Emamian, Hall et al. 2004; Lai, Xu et al. 2006).  
Putative evidence for a role of defects in mTORC2 signaling in mental illnesses preceded 
the discovery of the mTORC2 complex itself. Indeed, lithium, used to treat bipolar disorder, 
stimulates phosphorylation of Akt at S473, the mTORC2 phosphorylation site (Chalecka-
Franaszek and Chuang 1999).  The link between mTORC2 signaling deficits and mental illness 
has been strengthened by seminal work demonstrating that certain antidepressants (Krishnan, 
Han et al. 2008), along with both typical (Emamian, Hall et al. 2004) and atypical antipsychotics 
(Lu and Dwyer 2005) increase Akt S473 phosphorylation.  Furthermore, findings of diminished 
S473 phosphorylation and/or activity in post-mortem brains of patients with schizophrenia 
(Zhao, Ksiezak-Reding et al. 2006) and depression (Karege, Perroud et al. 2007) potentially 
fortify the association between dysregulation of mTORC2-Akt signaling and development of 
psychiatric illnesses, although these findings may be confounded by perimortem artifacts (Ide, 
Ohnishi et al. 2006).  Recent observations that blunted S473 phosphorylation occurs in 
lymphocytes derived from patients with schizophrenia and psychosis-prone normal individuals 
(Kéri, Seres et al. 2009) also support the plausibility that mTORC2-Akt deficits are involved in 
schizophrenia.  
  While human imaging and animal studies implicate a fundamental role for Akt signaling 
in prefrontal DA networks, the molecular mechanisms linking mTORC2/Akt to schizophrenia-
related neurotransmission abnormalities have been elusive (Lai, Xu et al. 2006; Tan, Nicodemus 
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et al. 2008).  Importantly, models of schizophrenia suggest that cortical deficits in DA 
neurotransmission and content defined here as cortical hypodopaminergia contributes to both the 
cognitive deficits and the negative symptoms characteristic of this disorder (Davis, Kahn et al. 
1991).  Consistent with this hypothesis, imaging studies reveal that genetic variation associated 
with low activity Akt alleles interact epistatically with catechol-O-methyltransferase (COMT), a 
gene responsible for degradation of prefrontal synaptic DA.  Together, these interactions 
ultimately affect the fidelity of prefrontal networks in humans (Tan, Nicodemus et al. 2008) by 
decreasing DA availability at prefrontal synapses (Lotta, Vidgren et al. 2002).  Thus, a 
compelling hypothesis in schizophrenia is that impaired mTORC2/Akt signaling triggers 
aberrant regulation of DA homeostasis.   
Termination of DA signaling at prefrontal synapses involves two mechanisms: 
degradation via enzymes including COMT, and clearance via the norepinephrine (NE) 
transporter (NET) (Gresch, Sved et al. 1995; Moron, Brockington et al. 2002; Miner, Schroeter 
et al. 2003), which takes up both major brain catecholamines, DA and NE (Yamamoto and 
Novotney 1998; Moron, Brockington et al. 2002).  Interestingly, insulin administration, which 
stimulates mTORC2/Akt signaling, decreases NET transcription in brain while, hypoinsulinemia, 
and decreased mTORC2/Akt signaling, increases NET transcription (Figlewicz, Brot et al. 
1996). Therefore, we hypothesized that dysregulation of mTORC2/Akt signaling may provide a 
mechanistic link to cortical hypodopaminergia. Specifically, we propose that reduced Akt 
activity mediates increased NET expression and increased DA clearance by noradrenergic 
neurons in cortex; a novel molecular mechanism that explains how Akt dysfunction contributes 
to prefrontal hypodopaminergia.   
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Figure 4.  Akt phosphorylation in cortex of neuronal Rictor null.
 
(A) Phosphorylation of Akt on residue S473 in the cortex. (B) Phosphorylation of Akt at T308 
and (C) total Akt in the cortex are similar for all genotypes. Shown are mean±s.e.m of optical 
densities as a percentage of FLOX control mice. Genotypes shown include animals expressing 
only nestin-CRE (NES), mice expressing two copies of the “floxed” rictor allele (FLOX) only, 
heterozygous mice which express nestin-CRE and a single copy of the “floxed” rictor allele 
(HET), and knockout mice expressing both nestin-CRE and two copies of the “floxed” rictor 
allele (KO). Total cortical protein extract was loaded in each lane. Representative immunoblots 
are shown, as probed with antibodies to phosphorylated Akt at S473 (A) T308 (B), total Akt (C), 
and actin to serve as a loading control. Samples n = 9–16. ***p<0.001 one-way ANOVA.  
Representative immunoblots are shown, as probed with antibodies to phosphorylated Akt at 
S473 (a) T308 (b), total Akt (c), and actin to serve as a loading control.  Samples n=9-16.  
***P<0.001 One-way ANOVA. 
 
To test this hypothesis, we have generated an animal model in which mTORC2/Akt 
signaling down-regulation is achieved by neuronal deletion of a key mTORC2 regulatory 
subunit, rictor.  We used a Cre-lox strategy to restrict the genetic deletion to neurons and bypass 
the embryonic lethality associated with whole body deletion (Shiota, Woo et al. 2006).  The goal 
of the present study is to test how alteration in Akt signaling affects dopamine homeostasis in the 
prefrontal cortex.  
 
Results 
 
Rictor deletion attenuates Akt S473 phosphorylation  
Akt deficiency is mechanistically linked to prefrontal cortex abnormalities and 
schizophrenia-linked phenotypes in several mouse models (Lai, Xu et al. 2006), although a clear 
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molecular mechanism for how Akt regulates cortical function remains elusive.  Here, we 
investigate the dopaminergic consequences of abolishing Akt phosphorylation at S473 in 
neurons by utilizing the Cre/LoxP system to delete Rictor specifically in neurons.  Mice were 
engineered with a floxed rictor allele, as previously described (Shiota, Woo et al. 2006) and 
crossed with neuron-specific nestin gene (NES mice) Cre driver line.  Validating our approach, 
rictor knockout mice (KO) lack rictor mRNA expression and rictor protein expression in a gene-
dosage dependent manner within the brain and cortex (Fig. S1; P < 0.01 and P < 0.05 
respectively, by one-way ANOVA followed by Dunnett’s test).  Importantly, for the current 
hypothesis, neuronal rictor deletion abolishes Akt phosphorylation at S473 within the cortex of 
rictor-nKO mice (Fig. 4a; ***P < 0.001 by one-way ANOVA Dunnett’s test) compared to FLOX 
(floxed allele(s) in the absence of Cre), NES (Cre allele in the absence of a FLOX allele), and 
heterozygous rictor neuronal knockout mice (HET).  Phosphorylation of Akt at T308 (Fig. 4b) 
and total levels of Akt (Fig. 4c) within the cortex are not different among the genotypes, 
allowing a direct evaluation of the effects of S473 phosphorylation.  Similarly, Rictor deletion 
also abolishes Akt phosphorylation at S473 in other brain regions, such as the substantia nigra 
(SN)/ventral tegmental area (VTA) of Rictor-nKO mice, while T308 phosphorylation and total 
levels of Akt are unaltered (data were normalized to control (FLOX) and reported as mean ± 
s.e.m., P values by Student’s t-test; pAkt S473 FLOX=100 ± 13%, KO=6 ± 1%, P < 0.001; pAkt 
T308 FLOX=100 ± 13%, KO=89 ± 8%, P = 0.49; total Akt FLOX=100 ± 13%, KO=101 ± 10%, 
P = 0.96).  Furthermore, total protein levels of mTOR in the cortex are not altered by neuron-
specific rictor knockout (data were normalized to control (FLOX) and reported as mean ± s.e.m.; 
FLOX=100 ± 9%, NES=130 ± 12%, HET=118 ±12%, KO=116 ± 12%; P = 0.32 by one-way 
ANOVA followed by Dunnett’s test).   
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Figure 5.  Neuronal Rictor deletion results in sensorimotor gating deficits as assayed by PPI.  
 
(a) No difference in startle reflex elicited by a 94 decibel (dB) sound pressure level (SPL) 
noise was observed between KO and littermate FLOX control mice.  (b)  The percentage of 
PPI was reduced significantly across the entire dB range in KO mice.  (c) The average PPI 
across the entire dB range reveals a significant deficit in PPI in KO mice; n=6-7 animals.  
*P<0.05 Student’s t-test 
 
 
Neuronal Rictor-nKO mice display sensorimotor gating deficits  
Pre-pulse inhibition (PPI) behavior has long been identified as a promising phenotype for 
translational studies of schizophrenia owing to the direct parallels in expression between rodent 
and human subjects.  While PPI deficits are present in psychiatric disorders other than 
schizophrenia, they have a clear heritable component in schizophrenic families and these deficits 
can be attenuated by antipsychotic drug administration.  Furthermore, PPI deficits are also linked 
to the hypofunction of corticostriatal forebrain circuits which is characteristic of schizophrenia 
(Powell, Zhou et al. 2009).  The PPI behavioral assay measures the degree to which the startle 
response elicited by a loud “pulse” sound is attenuated when immediately preceded by a non-
startling “prepulse” sound.  As such, it assays the degree to which a brief sensory trace can 
rapidly modify a subsequent motoric response, thereby representing a straightforward approach 
towards quantifying sensorimotor dysregulation, which is generally regarded as an 
endophenotype of schizophrenia.  Since evidence suggests a role for Akt in schizophrenia, and 
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rictor-nKO mice demonstrate profound deficits in Akt phosphorylation, we tested whether rictor-
nKO mice display impaired PPI relative to FLOX control mice.  No differences in startle 
responses elicited by a 94 dB sound pressure level (SPL) noise burst were observed, suggesting 
that hearing and gross motor function were similar between groups (Fig. 5a; Student’s t-test; P = 
0.44).  By contrast, analysis of PPI behavior revealed clear differences between genotypes; 
startle reflex amplitude was inhibited at all prepulse intensities in FLOX control mice, with the 
amount of PPI increasing monotonically from 40 to 75 dB SPL (Fig. 5b).  In rictor-nKO mice, 
prepulse sound levels between 40-55 dB did not appreciably attenuate the startle reflex.  PPI was 
not observed in rictor-nKO mice until prepulse levels > 55 dB, albeit at a weaker level in 
comparison to FLOX mice.  These differences gave rise to a significant reduction of PPI across 
prepulse sound levels (Fig. 5b; *P < 0.05 by ANOVA).  This PPI deficit can also be expressed as 
a significant decrease in average PPI across all sound levels in rictor-nKO mice (Fig. 5c; 
Student’s t-test, *P < 0.05).  Thus, neuronal Rictor deletion with loss of Akt S473 
phosphorylation impairs the forebrain circuits critically involved with sensorimotor integration.  
Given the strong evidence for PPI deficits in schizophrenic patients, we hypothesize that this 
mouse model has the potential to lend novel insight into the molecular mechanisms by which 
Akt deficits contribute to the schizophrenic phenotype.   
 
Rictor-nKO mice display hypodopaminergia in rostral cortex  For almost fifty years, 
schizophrenia research has centered on dopaminergic signaling as a crucial component of the 
etiology of the disease (Delay, Deniker et al. 1952; Carlsson and Lindqvist 1963; Seeman and 
Lee 1975).  In particular, the original “DA hypothesis” heavily supported the notion of excessive 
DA neurotransmission and DA content, defined here as hyperdopaminergia, within the brain 
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(Matthysse 1973; Snyder 1976).  Subsequent revision of the hypothesis however has transformed 
thinking from a global hyperdopaminergia to a regional hyperdopaminergia within the striatum 
and dopaminergic hypofunction within the cortex (Weinberger, Berman et al. 1988; Davis, Kahn 
et al. 1991; Howes and Kapur 2009).  While this conceptualization is an oversimplification of a 
highly complex disorder, we utilized this hypothesis to hone in on molecular mechanisms that 
contribute to cortical hypodopaminergia.  Furthermore, previous studies have linked pre-frontal 
dopamine deficits with PPI deficits in animal models, and perhaps the PPI deficits observed in 
the Rictor-nKO mice could be partially explained by alterations in cortical DA content (Koch 
and Bubser 1994; Swerdlow, Shoemaker et al. 2006).  Thus, we investigated steady state levels 
of dopamine (DA), serotonin (5-HT), and norepinephrine (NE) in a region of mouse brain that is 
roughly analogous to the human prefrontal cortex and contains areas such as the infralimbic, 
prelimbic, and anterior cingulate cortex.  Interestingly, HPLC with electrochemical detection of 
DA, NE, and 5-HT in the PFC of rictor-nKO mice revealed striking alterations in the DA and NE 
tissue content of these animals, while 5-HT levels remained unchanged (Fig. 6).  While both DA 
and NE levels are significantly different in rictor-nKO mice they change in opposite directions; 
NE tissue content is significantly increased (Fig. 6a; **P < 0.01 by one-way ANOVA followed 
by Dunnett’s test) while DA levels are significantly decreased (Fig. 6b; Student’s t-test, *P < 
0.05).  In addition, NES mice show similar PFC DA content levels (6.4±0.2 ng/mg protein) as 
FLOX mice.  Thus, Rictor-nKO mice display a key feature of the “dopamine hypothesis” of 
schizophrenia, namely hypodopaminergia in the rostral cortex, which may explain the 
sensorimotor gating deficits described earlier.  Importantly, 5-HT levels are unaltered in the 
cortex (Fig. 6c; Student’s t-test, P=0.26) indicating that rictor deletion does not simply result in 
global monoaminergic alterations but rather specific changes in the dopaminergic and 
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Figure 6.  Monoamine content in the rostral cortex is significantly altered in rictor-nKO 
mice.   
Tissue content of (a) NE, (b) DA, and (c) serotonin (5-HT) in rostral cortical homogenates.    
Results are presented as mean ± s.e.m ng/mg of protein, n=4-10. *P<0.05; **P<0.01 
Student’s t-test. 
 
noradrenergic systems.  In addition, extracellular levels of DA and NE were determined in the 
PFC of Rictor-nKO mice by microdialysis.  Under basal conditions, extracellular DA is not 
significantly different in Rictor-nKO mice compared to FLOX controls (data are reported as pg 
of DA/µL, mean ± s.e.m.; FLOX=0.54 ± 0.15, KO=0.76 ± 0.18, P = 0.35 by Student’s t-test).  
However, basal levels of extracellular NE, are significantly decreased in Rictor-nKO mice (data 
are reported as pg of NE/µL, mean ± s.e.m.; FLOX=14.8 ± 3.4, KO=6.2 ± 1.5, P < 0.05 by 
Student’s t-test).  While basal extracellular levels of DA are unaltered in rictor-nKO mice, these 
animals do display significant deficits in DA tissue content suggesting that maintenance of DA 
homeostasis is perturbed.   
While prefrontal hypodopaminergia has been linked to PPI deficits, other studies clearly 
demonstrate a link between striatal hyperdopaminergia and PPI deficits (Ralph, Varty et al. 
1999; Ralph 2001).  Thus, we sought to determine if Rictor deletion increases tissue levels of DA 
in projecting DA neurons from the SN and VTA.  DA levels in the SN/VTA are not altered in 
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rictor-nKO mice (data are reported as ng of DA/mg protein, mean ± s.e.m.; FLOX=4.4 ± 0.5, 
KO=4.8 ± 0.4, P = 0.60 by Student’s t-test).  Thus, our data indicates that the PPI deficits 
observed in rictor-nKO mice are likely to arise from impairments in DA neurotransmission. 
 
Rictor deletion increases NET expression and function 
It is intriguing that DA content is decreased while NE content is increased in Rictor-nKO 
mice.  Importantly, decreases in mTORC2/Akt signaling induced by hypoinsulinemia have been 
shown to increase NET transcription (Figlewicz, Brot et al. 1996).  Moreover, early studies and 
unpublished data from our laboratory implicate deficits in Akt signaling with not only increases 
in NET transcription, but also with acute increases in NET cell surface expression (i.e. intact Akt 
signaling decreases NET availability at the plasma membrane) (Boyd, Clarke et al. 1986; 
Figlewicz, Szot et al. 1993; Figlewicz, Brot et al. 1996). Thus, we predict that altered DA 
homeostasis in Rictor-nKO mice is due to changes in NET cell surface expression mediated by 
impaired Akt phosphorylation.  Importantly, unlike other brain regions where DAT is the 
primary mechanism for removing DA from the synapse, in cortex DAT contributes relatively 
little and NET performs the majority of DA clearance.  Indeed NET has a higher affinity for DA 
than NE itself, but DA can also be degraded in the synapse by catechol-o-methyltransferase 
(COMT) (Moron, Brockington et al. 2002; Miner, Schroeter et al. 2003).  Given the pivotal role 
of Rictor in Akt regulation and the role of Akt signaling in determining NET availability, we 
hypothesize that Rictor-nKO mice will display aberrant NET regulation that sustains the 
alterations in NE and DA levels seen in the rostral cortex.   
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Figure 7.  Neuronal Rictor deletion results in increased NET expression and function.  
 
(a) NET protein levels in the cortex.  Mean ± s.e.m optical densities are shown as a 
percentage of FLOX control mice.  Representative immunoblots are shown, as probed with 
antibodies to NET, and actin (loading control); n=10.  (b) Levels of surface NET as measured 
from the biotinylated fraction of cortical slices.  Mean ± s.e.m optical density is shown as a 
percentage of FLOX control mice. Representative immunoblots are shown, as probed with 
antibodies to NET, Na
+
/K
+
 ATPase to serve as plasma membrane/loading control (n=3-5), 
and TH which is absent in the biotinylated fractions since it is a cytosolic protein. (c) [
3
H]NE 
and [
3
H]DA uptake into cortical synaptosomes of FLOX and KO mice.  Mean ± s.e.m uptake 
is shown as a percentage of uptake in FLOX control mice; n=12-18 *P<0.05; ***P<0.001 
Student’s t-test. 
 
As hypothesized, total cortical NET protein is increased approximately two-fold in rictor-
nKO mice compared to all other genotypes (Fig. 7a; ***P < 0.0001 by one-way ANOVA 
followed by Dunnett’s test).  Furthermore, biotinylation assays reveal that cell surface levels of 
NET are also significantly increased (Fig. 7b; Student’s t-test, ***P<0.0001).  Tyrosine 
hydroxylase (TH), a cytosolic protein, was detected exclusively in the total protein fraction but 
not in the surface fraction, indicating that the biotinylated fraction represents exclusively cell 
surface proteins.  Finally, the striking enhancement in surface NET detected in Rictor-nKO mice 
results in a significant increase in NET function as assayed by cortical synaptosomal NE uptake 
(Fig. 7c; Student’s t-test, *P<0.05).  The nearly two-fold increase in cortical synaptosomal NE 
uptake was also observed for DA (Fig. 7c; Student’s t-test, *P<0.05) indicating that rictor 
deletion increases DA clearance by NET in noradrenergic neurons and as a consequence reduces 
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Figure 8.   Akt1 inhibition enhances NET surface availability in cortical slices.    
 
 (a) Levels of NET as measured from the different fractions (surface, total) of cortical slices from 
NES control mice.  Slices were treated with either vehicle-DMSO (CTR) or 12 µM of the Akt1 
inhibitor.  Mean ± s.e.m optical density were normalized to total NET and are shown as a 
percentage of CTR. Representative immunoblots are shown, as probed with antibodies to NET, 
Na
+
/K
+
 ATPase to serve as plasma membrane/loading control; n=4, *P<0.05 Student’s t-test. (b) 
Phosphorylation of Akt on residue Ser473 measured from the same samples as panel A.  Mean ± 
s.e.m of optical densities normalized to total Akt and shown as a percentage of CTR; n=4, 
***P<0.001 Student’s t-test. 
 
cortical DA content.  Furthermore, DA content is not decreased due to increased degradation 
since COMT levels were not different in cortex compared to FLOX control mice (data were 
normalized to control (FLOX) and reported as mean ± s.e.m.; FLOX=100 ± 8%, NES=78 ± 11%, 
HET=130 ±24%, KO=80 ± 11%; P = 0.10 by one-way ANOVA followed by Dunnett’s test).  
Thus, the increase in NET expression and function within the cortex of Rictor-nKO mice has the 
potential to mechanistically explain both the increased NE tissue content and decreased cortical 
DA tissue content described earlier (Fig. 6).  While our data indicates that global neuronal 
mTORC2 dysfunction enhances NET function and induces cortical hypodopaminergia, we 
sought to demonstrate more specifically that these alterations could arise from downregulation of 
cortical Akt activity.  Thus, we utilized the isoform specific Akt1 inhibitor (DeFeo-Jones, 
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Barnett et al. 2005; Lindsley, Zhao et al. 2005; She, Chandarlapaty et al. 2008) in cortical slices 
to show that Akt inhibition, rather than rictor manipulation, is capable of determining NET 
surface availability (Fig. 8).  Surface levels of NET are significantly enhanced in biotinylated 
cortical slices treated with the Akt1 inhibitor (Fig. 8a; *P < 0.05 by Student’s t-test).  
Importantly, the levels of Akt S473 phosphorylation are substantially diminished in samples of 
these inhibitor treated slices (Fig. 8b; ***P < 0.0001).  Together, these data support the notion 
that Akt stimulated regulation of the transporter occurs not only at the level of transcription, as is 
seen in rictor-nKO mice, but also at the level of transporter trafficking.  Furthermore, the ability 
of Akt inhibition to enhance NET surface expression in cortical slices indicates that all the 
molecular machinery necessary for this rictor/Akt regulation of NET is intact within the PFC, 
and thus most likely does not require additional afferent connections or neural circuitry. 
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Figure 9.  TH staining and expression in the midbrain and cortex is similar in NES, FLOX, and 
KO mice.   
 
 
TH immunoreactivity in the (a) midbrain substantia nigra (SN) and ventral tegmental area 
(VTA) and the (b) cortex.  Scale bars = 50 µm. Coronal brain sections were stained with TH 
antibody and cell counts of TH
+
 cells were taken.  Cell counts are similar in NES, FLOX, and 
KO matched mice in both the (c) VTA and the (d) SN.  Mean ± s.e.m TH
+
 cells/mm
2
 are shown; 
n=6.  (e) TH protein levels in the cortex.  Mean ± s.e.m optical densities are shown as a 
percentage of FLOX control mice; n=19-22.  One-way ANOVA analysis reveals no significant 
difference between genotypes.   
 We hypothesize that amplified NET function in Rictor-nKO mice enhances the 
accumulation of both NE and DA within the noradrenergic neuron leading to conversion of DA 
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to NE and ultimately supporting both increased NE tissue content and a state of 
hypodopaminergia.  Such a mechanism within the prefrontal cortex provides an elegant 
molecular mechanism linking Akt hypophosphorylation to both cortical hypodopaminergia and 8 
 
Midbrain dopaminergic neurons and cortical monoaminergic projections are unaltered in 
Rictor-nKO mice 
 
 Considering the widespread function of Akt, and its role in cell growth and proliferation, 
we next sought to demonstrate that the changes in DA and NE levels within the cortex were 
specifically due to increased NET expression rather than global changes in the number or 
projections of dopaminergic and noradrenergic neurons.  While Rictor-nKO mice do display a 
gross reduction in brain size, similar to what is seen for Akt3 deficient mice (brain weight 
normalized to body weight; FLOX 2.49 ± 0.18% compared to KO 1.63 ± 0.10%; P < 0.0005 by 
one-way ANOVA followed by Dunnett’s test), coronal brain sections stained for TH revealed no 
significant alterations in dopaminergic cell number within the VTA or SN (Fig 9a and 9c-d; 
VTA P = 0.82 by one-way ANOVA, SN P = 0.53 by one-way ANOVA).  Furthermore, TH 
staining of dopaminergic and noradrenergic projections within the cortex do not reveal any gross 
alterations among the groups (Fig. 9b). The immunostaining was confirmed with western blot 
analysis of total cortical TH protein levels (Fig. 9e; P = 0.20 by one-way ANOVA).  Other 
markers of dopaminergic neurons in the cortex were not significantly altered in the Rictor-nKO 
mice such as total levels of D2 dopamine receptors (data were normalized to control (FLOX) and 
reported as mean ± s.e.m.; FLOX=100 ± 5%, NES=95 ± 13%, HET=96 ±9%, KO=108 ± 18%; P 
= 0.85 by one-way ANOVA followed by Dunnett’s test).  These data demonstrate that the DA 
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and noradrenergic systems in the Rictor-nKO mice are not globally altered.  Therefore, we 
propose that the changes in cortical NE and DA tissue content can be primarily accounted for the 
specific enhancement of NET expression in noradrenergic neurons. 
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Figure 10.  Nisoxetine restores PPI deficits and DA levels in the rostral cortex of Rictor-nKO mice.  
 
 
(a) panel b and d are cutNo differences are observed in the average %PPI across the experimental 
range of dB in KO mice prior to treatment with saline or nisoxetine.  (b) Average %PPI 30 min after 
i.p. injection of either saline or nisoxetine (30mg/kg) in KO mice reveals a significant increase in 
%PPI in nisoxetine treated KO mice.  (c) The mean PPI across all sound levels in KO mice treated 
with either saline or nisoxetine for 30 min; n=5-6, ***P<0.001 Student’s t-test.  (d) 8 days of 
nisoxetine treatment restores DA levels in the rostral cortex of rictor-nKO mice; n=4-6. *P<0.05 
Student’s t-test. 
 
 
 50 
NET blockade reverses the sensorimotor gating deficits and hypodopaminergia in rictor-nKO 
mice 
 We hypothesize that aberrant Akt phosphorylation in Rictor-nKO mice results in 
enhancement of NET function within the cortex, resulting in changes in both DA and NE 
homeostasis.  If this model is valid, then NET inhibition should reverse both PPI behavioral 
deficits and cortical deficits in DA tissue content.  In order to test this mechanism, we treated 
Rictor-nKO mice with nisoxetine (NET specific blocker) or saline.  Prior to treatment, both 
groups of Rictor-nKO mice demonstrated comparable startle reflex amplitude similar to Fig. 5b 
(data not shown).  The average PPI across all sound levels also were not different between the 
two Rictor-nKO groups prior to treatment (Fig. 10a; Student’s t-test, P = 0.95).  Following the 
initial PPI trial, the Rictor-nKO mice received i.p. injections of either saline or nisoxetine (30 
mg/kg) and 30 minutes later began a second PPI trial.  Nisoxetine reversed Rictor-nKO PPI 
deficits compared to saline treated animals with a ~5 fold increase of average PPI (Fig. 10b 
Student’s t-test, ***P<0.0001).  Similar to FLOX control mice (Fig. 10b), nisoxetine treated 
Rictor-nKO mice display startle reflex amplitudes that are inhibited by all prepulse intensities, 
with the amount of PPI increasing monotonically from 40 – 75 dB SPL (Fig. 10c).  Importantly, 
saline treated animals exhibited PPI at prepulse levels > 55 dB, albeit at a weaker level as 
compared to nisoxetine treated animals, consistent with Fig. 5b.  Thus, nisoxetine treatment 
significantly reverses the PPI deficits observed in Rictor-nKO mice (Fig. 10c; P < 0.0001 by two 
way ANOVA) providing support for our model of mechanistic linkage between Akt, NET, and 
cortical DA and NE homeostasis.   
In addition to nisoxetine treatment, we sought to determine if traditional antipsychotics 
were capable of reversing the PPI deficits displayed in Rictor-nKO mice.  Unlike nisoxetine, 
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acute clozapine treatment (i.p. 3 mg/kg for 30 minutes prior to PPI) did not rescue PPI deficits in 
Rictor-nKO mice (data are reported as average percent PPI mean ± s.e.m. as in Fig. 5c; saline-
KO 24.3 ± 8.6%, clozapine-KO 20.5 ± 6.4%; Student’s t-test,  P = 0.73).  Interestingly, previous 
studies have shown that antipsychotic treatment enhances activity and phosphorylation of Akt at 
S473, and this increase is hypothesized to be important for the efficacy of such drugs (Emamian, 
Hall et al. 2004; Kang, Seo et al. 2004; Roh, Seo et al. 2007).  Consistently, FLOX mice 
subjected to the same clozapine treatment as described above show significantly enhanced 
cortical phosphorylation of Akt at S473 (data are normalized to total levels of Akt and expressed 
as percent of control mean ± s.e.m.; saline-FLOX 100 ± 20%, clozapine-FLOX 215 ± 50%; *P < 
0.05 by one way ANOVA). Importantly, the same treatment does not alter S473 phosphorylation 
of Akt in rictor-nKO mice (data are normalized to total levels of Akt and expressed as percent of 
control (saline treated FLOX) mean ± s.e.m.; saline-KO 5 ± 1%, clozapine-KO 5 ± 2%; P > 0.05 
by one way ANOVA).  Thus, the inability of clozapine to rescue PPI deficits in Rictor-nKO mice 
may be partially due to the genetic neuronal deletion of rictor, which abolishes the ability of 
clozapine to enhance Akt S473 phosphorylation in these animals.  These data are consistent with 
the hypothesis that Akt deficits play an important role in the etiology of schizophrenia, and that 
perhaps some degree of antipsychotic efficacy is due to their ability to enhance Akt function. 
The success of nisoxetine treatment in rescuing the PPI deficits in rictor-nKO mice was 
consistent with our model and led us next to determine if NET inhibition could normalize 
prefrontal cortex DA tissue content.  In this experiment, Rictor-nKO and FLOX control mice 
received either nisoxetine (30 mg/kg) or saline injections i.p. daily for eight consecutive days and 
were euthanized 30 min following their last i.p. injection. DA levels were measured in the rostral 
cortex by electrochemical detection.  Similar to the results seen in Fig. 6, saline treated Rictor-
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nKO mice had reduced DA tissue content levels in comparison to saline treated controls (Fig. 
10d; Student’s t-test, *P<0.04) and 8 days of nisoxetine treatment significantly enhanced DA 
content (Fig. 10d; Student’s t-test, *P<0.03) while the same treatment in FLOX control mice did 
not have a significant impact on DA levels (Fig. 9d; Student’s t-test, P = 0.21).  Moreover, 
chronic nisoxetine treatment does not significantly alter cortical NE tissue content in either 
FLOX control or Rictor-nKO mice (data are reported as ng of NE/mg protein, mean ± s.e.m.; 
FLOX-saline=5.7 ± 0.4, FLOX-nisoxetine=6.5 ± 0.5, Student’s t-test, P = 0.29; KO-saline=8.3 ± 
0.7, KO-nisoxetine=8.6 ± 0.4, Student’s t-test, P = 0.74).  These data further support the model 
that enhanced NET expression alters DA content in the Rictor-nKO mice, and indicate that 
hypodopaminergia (and PPI deficits) can be rectified with NET specific inhibition via nisoxetine.  
The observations that chronic nisoxetine administration rescues DA content and acute treatment 
reverses impaired PPI are consistent with a model whereby impairment of PPI is due to 
decreased intra-synaptic DA in Rictor-nKO mice.  Our data suggest that reduced intra-synaptic 
DA content could arise from enhanced clearance of DA via NET.   
NET specific inhibition with nisoxetine has been utilized to rectify PPI deficits in some 
animal models of schizophrenia (Yamashita, Fukushima et al. 2006).  Only a small number of 
studies, however, have investigated the utility of NET specific inhibition in schizophrenic 
patients with a particular focus on symptoms related to cortical hypofunction, and the efficacy of 
such treatment is still controversial (Kelly, Buchanan et al. 2009).  Currently, a number of 
additional clinical trials with substantial sample sizes are ongoing and promise to reveal if NET 
specific inhibition is therapeutic in schizophrenia especially for cognitive symptoms such as poor 
concentration and memory (clinicaltrials.gov).   
 
 53 
Discussion 
 
The “dopamine hypothesis” for schizophrenia has enjoyed a resurgence of interest with 
increasing evidence for a role of Akt in DA related behaviors, yet key molecular mechanisms 
linking Akt to DA homeostasis have been elusive.  Given evidence for a role of Akt in the 
regulation of NET expression and function in cortex and evidence that NET transports DA in this 
brain area, it has been our priority to develop a compelling experimental model to uncover a 
molecular link between Akt and cortical DA homeostasis.  Here, we conducted the first studies, 
to our knowledge, in an animal model where a genetic deletion that disrupts Akt phosphorylation 
enhances expression of NET and leads to a cortical hypodopaminergic phenotype with 
schizophrenia-linked behavioral consequences.   
Our data are consistent with pathophysiological models of schizophrenia that emphasize 
“hypofrontality” of DA systems.  Given the role of NET in DA clearance in prefrontal synapses 
(Carvelli, Moron et al. 2002; Moron, Brockington et al. 2002; Miner, Schroeter et al. 2003), Akt-
linked changes in NET expression may thereby translate to cognitive deficits and negative 
symptoms (Davis, Kahn et al. 1991).  These data, as well as our proof-of-principle results in 
mice, lead to the compelling hypothesis that NET inhibition would have therapeutic potential to 
selectively enhance DA tone in the prefrontal cortex and perhaps alleviate negative symptoms.  
Consistent with this reasoning, several clinical trials are currently investigating NET blockers for 
cognitive deficits in patients with schizophrenia.   
Our data demonstrate that neuronal mTORC2 dysfunction is sufficient to generate 
cortical hypodopaminergia and schizophrenia-linked behaviors.  In particular, we show that 
genetic mTORC2 disruption impairs PPI, a schizophrenia-linked phenotype, which has been 
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validated in genetic mouse models of the disorder (Powell, Zhou et al. 2009).  An emerging body 
of evidence associates Akt phosphorylation deficits with mental illness in humans, giving our 
findings of impaired Akt phosphorylation in mice more translational viability (Emamian, Hall et 
al. 2004; Keri, Beniczky et al. 2010).  For example, studies show diminished Akt1 protein 
content in lymphocytes of patients with schizophrenia (Emamian, Hall et al. 2004; Kéri, Seres et 
al. 2009).  In concert with our findings,  candidate gene approaches aimed at identifying genetic 
variation in proteins associated with mTORC2/Akt signaling pathways, including rictor and 
other mTORC2 subunit proteins like mSin1 (Jacinto, Facchinetti et al. 2006) may yield new 
insights into the genetic basis of mental illness.  
While DA is classically implicated in the pathogenesis of schizophrenia, concepts of 
neurotransmitter dysfunction in this disease process are constantly evolving.  This is reflected by 
popular glutamatergic and recently proposed revisions to dopaminergic hypotheses of 
schizophrenia(Howes and Kapur 2009).  However, the role of elevated cortical NE, while not 
typically emphasized, should not be overlooked.  Indeed, findings of elevated NE in CSF of 
patients with schizophrenia, which led to noradrenergic hypotheses of schizophrenia in the early 
1980’s (Lake, Sternberg et al. 1980), support our model by which increased cortical NET 
expression leads to increased NE content but decreased DA content.  While the sensitivity of 
these measurements to acute stressors made the reproducibility and reliability of these methods 
in the aforementioned studies questionable, a role for elevated NE in the development of 
schizophrenia-like phenotypes in humans cannot be completely ruled out.  Indeed, our current 
findings, as well as others, intimately and mechanistically link DA alterations together with NE 
changes (Ventura, Cabib et al. 2003).  As a recent revision to the DA hypothesis of 
schizophrenia suggests, schizophrenia could be conceptualized as a disease where DA 
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dysfunction is a “final common pathway” that can be elicited by a number of more proximal 
causes, including both genetic and epigenetic factors and disruption in other neurotransmitter 
systems (Howes and Kapur 2009), and including, as we propose here, increased NET function. 
Schizophrenia is thought to arise from rather complex gene-environment interactions, 
and, therefore, acquired (rather than monogenetic) dysfunction in mTORC2/Akt signaling is a 
particularly intriguing mechanism.  For example, acquired Akt defects are associated with 
impaired regulation of blood glucose and diabetes, which is over-represented in first episode, 
medication-naive patients with schizophrenia (Ryan, Collins et al. 2003).  mTORC2/Akt 
signaling also provides a promising portal into “multiple hit” models of schizophrenia, as Akt is 
positioned to interact with other candidate genes such as neuregulin-1 and COMT (Kanakry, Li 
et al. 2007; Tan, Nicodemus et al. 2008) as well as environmental risk factors for schizophrenia 
including obstetric complications and early life stressors (Krishnan, Han et al. 2008; Nicodemus, 
Marenco et al. 2008).  The effects of neuronal mTORC2 dysfunction on NET expression 
observed in our study ultimately illustrates a potential molecular mechanism to link disparate 
genetic and environmental factors (i.e. obesity/diabetes/insulin resistance) to dysfunction in a 
putative “final common pathway” of schizophrenia, namely alterations in DA signaling (Howes 
and Kapur 2009).  Indeed, while more remains to be learned about mTORC2, deficiencies in Akt 
signaling even in “healthy” individuals are associated with impaired prefrontal cortex activation 
on working memory tasks (Tan, Nicodemus et al. 2008) and proneness to psychosis, suggesting a 
subtle influence on brain function and behavior that may require other genetic and environmental 
hits to result in clinical disease.  Thus, our data provide one molecular mechanism, NET 
regulation, towards a framework linking environmental stressors and/or lifestyle factors to 
mTORC2/Akt signaling and ultimately to DA dependent behaviors.  Our studies provide a 
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potential molecular mechanism linking Akt dysfunction to a schizophrenia-like phenotype and 
suggest the viability of targeting both Akt phosphorylation and NET as pharmacotherapies for 
schizophrenia. 
 
Methods 
 
All procedures were performed according to Vanderbilt University Institutional Animal Care and 
Use Committee approved procedures. 
Generation of mice. All mice were fully backcrossed to C57Bl6 background.  Mice 
homozygous for an allele containing LoxP sites flanking exon 3 of the rictor gene (rictor f/f Nes-
/-; FLOX) were crossed with neuron specific Nestin cre transgenic mice (rictorw/w Nes+/+; 
NES) obtained from Jackson Laboratories to create double heterozygous (rictorf/w NesCre+/-; 
HET) offspring (w is the wildtype allele). HET mice were then crossed to produce neuron 
specific rictor knockout mice (rictor f/f Nes+/+ or +/-; KO) and HET KO mice. Control animals 
were of the following genotypes (rictorf/f Nes-/- FLOX,  rictorf/w Nes-/- and rictorw/w Nes+/+,  
Nes+/- or Nes-/-). Subsequent crossings between FLOX and HET mice were used to generate 
additional study animals.  Genotyping was performed by PCR using DNA obtained from tail 
clippings with primers for the floxed, nestin and recombined alleles as described(Shiota, Woo et 
al. 2006).  
 
mRNA expression. Total brain RNA was extracted from with Trizol reagent (Invitrogen). 
cDNA was synthesized with a High Capacity cDNA reverse transcription kit (Applied 
Biosystems). rictor mRNA was quantified with real time RT PCR on a Bio-Rad iCycler using iQ 
 57 
SYBR green Supermix reagent (Bio-Rad) and primer pairs as reported in (Shiota, Woo et al. 
2006). Expression was normalized to levels of the housekeeping gene RPL13.  
 
Immunoblot analysis.  Mice were anesthetized with volatile isoflurane after which rapid 
decapitation allowed brain removal.  Brains were chilled on ice and dissected using a scope for 
either total cortex, rostral cortex, or caudal cortex.  Tissue was homogenized and lysed in a 
Triton based buffer that contained a cocktail of protease inhibitors plus NaF (2mM) and sodium 
orthovanadate (2mM).  After homogenization samples were centrifuged at 17,000Xg for 30 min, 
and the supernatant was collected and processed for protein concentration determination.  For 
western blotting, ≈30µg of protein per sample was run on a 10-12% acrylamide gel, transferred 
to a PVDF membrane blocked with 5% milk and incubated with primary antibodies to a variety 
of proteins.  Akt, rictor, and mTOR antibodies were obtained from Cell Signaling.  We also used 
actin (Sigma), Na+/K+ ATPase (DBH), NET (Mab Technologies Inc. NET05-2), and tyrosine 
hydroxylase (Chemicon/Millipore) antibodies. Secondary antibodies were obtained from Santa 
Cruz Biotechnology.  After chemiluminescent visualization on Hyper-film ECL film, protein 
band densities were quantified and analyzed (Scion Image; http://www.scioncorp.com). 
 
Pre-pulse inhibition. Startle responses were elicited with a 94 dB SPL broadband noise burst (2-
75 kHz, 50 ms duration, 0 ms rise/fall time) and measured through a floor plate mounted on 
piezo force transducers (PCB Piezotronics).  In two-thirds of the trials, the noise burst (pulse) 
was preceded by a prepulse (2.4-78.2 kHz frequency-modulated sweep, 40 octaves/s, 0.14 ms 
stimulus onset asynchrony) ranging from 40-75 dB SPL.  Startle responses were measured across 
297 trials (20 ± 6.4 sec intertrial interval, initial 27 trials discarded to minimize within-session 
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habituation), as max – min of the force signal within 400 ms following onset of the noise burst.   
Presence of a normal startle response (significant difference between force plate amplitude -600 
to -200 ms (baseline) vs. 0-400 ms (startle) from noise burst onset) was a prerequisite for 
subsequent analysis to minimize possible contributions of gross sensorimotor deficits in either 
genotype.  This criterion excluded 2/8 WT and 0/7 rictor-nKO mice from further analysis.  
Inhibition of the startle reflex was quantified for each prepulse intensity as PPI = 100 x ((pulse-
alone) – (prepulse + pulse) / pulse alone). 
 
Tissue extraction for neurochemistry. Brain sections were homogenized in 100-750 ul of 0.1M 
TCA, which contains 10-2 M sodium acetate, 10-4 M EDTA, 5ng/ml isoproterenol (as internal 
standard) and 10.5 % methanol (pH 3.8).  Samples were spun in a microcentrifuge at 10000 g for 
20 minutes, the supernatant removed and stored at –80 ºC.  The pellet was saved for protein 
analysis.  Supernatant was then thawed and spun for 20 minutes and then analyzed for biogenic 
monoamines and/or amino acids by a specific HPLC assay (Vanderbilt Neurochemistry Core).  
Biogenic amines were eluted in the following order: NE, MHPG, epinephrine, DOPAC, DA, 5-
HIAA, HVA, 5-HT, and 3-MT (2).   
 
In vivo microdialysis. Mice were anesthetized with isoflurane and placed in a stereotaxic frame 
using mouse-specific ear bars (Kopf Instruments, Tujunga, CA). A guide cannula (CMA7 
microdialysis, USA) was placed above the medial prefrontal cortex (+2.0 AP, ± 0.7 ML from 
Bregma and -1.0 DV from skull for FLOX or NES mice and (+1.9 AP, ± 0.6 ML from Bregma 
and -1.0 DV from skull for rictor-nKO mice and secured to the skull with epoxy adhesive 
(Plastics one). Animals were allowed to recover from the surgery (1-3 days). The day before the 
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experiment, animals were placed in individual dialysis chambers and the microdialysis probe 
(CMA7 microdialysis, USA) with the active length of 2 mm was inserted into the guide cannula.  
One end of a tether (Plastics One) is attached to a harness and the other end attached to a swivel 
(Instech) that is mounted on a counterbalanced arm above the dialysis chamber. The probe was 
perfused overnight at a flow rate of 0.5 μL/min with artificial cerebral spinal fluid containing 149 
mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 5.4 mM d-glucose, pH 7.2.  On the day 
of the experiment the flow rate was changed to 1.0 μL/min and after equilibration dialysis 
fractions (20 min each) were collected to establish baseline concentrations of neurotransmitter 
efflux.  Dialysate samples were stored at -80°C and analyzed by HPLC-EC for monoamine 
levels.  
 
Brain slice preparation and biotinylation. Brain slices were prepared from 6- to 10-week-old 
mice that were anesthetized with isoflurane and rapidly decapitated.  Following, brain removal 
the brain was chilled in oxygenated ≈4°C sucrose solution (sucrose 210mM; NaCl 20mM; KCl 
2.5mM; MgCl2 1mM; NaH2PO4•H2O 1.2mM), and then while in sucrose solution 300µm 
coronal slices were made using a vibratome.  Slices were then collected in oxygenated artificial 
cerebral spinal fluid (ACSF) (NaCl 125mM, KCl 2.5mM,   NaH2PO4•H2O 1.2mM, MgCl2 
1mM, CaCl2•2H2O 2mM).  For in vitro drug treatments slices were then allowed to recover for 
1 hour at 37°C in oxygenated ACSF (NaCl 125mM, KCl 2.5mM, 1nM insulin,  NaH2PO4•H2O 
1.2mM, MgCl2 1mM, CaCl2•2H2O 2mM)with either vehicle or Akt1 inhibitor and following 
recovery slices were then biotinylated.  For non-treated slices, slices were immediately washed 
twice with oxygenated 4°C ACSF following collection, and then incubated with 4°C ACSF 
solution containing 1mg/mL of EZ-Link Sulfo-NHS-SS-Biotin (Pierce/ThermoScientific; 
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Rockford, IL.) for 45 min.  Slices were then washed twice with oxygenated 4°C ACSF, and then 
incubated with 4°C ACSF solution containing 1mg/mL of EZ-Link Sulfo-NHS-SS-Biotin 
(Pierce Chemical; Rockford, IL) for 45min.  After biotin incubation, the slices were rinsed twice 
quickly and for two 10 min washes in oxygenated 4°C ACSF.  The reaction was quenched by 
washing twice for 20 min each with oxygenated 4°C ACSF containing glycine.  Following 
quenching, slices were frozen on dry ice and the cortex was cut out and frozen at -80°C until 
used.  Slices were lysed in 1% Triton buffer (25mM Hepes, 150mM NaCl, 2mM sodium 
orthovanadate, 2mM NaF, plus a cocktail of protease inhibitors) and centrifuged at 17,000g for 
30min at 4°C.  After isolation of supernatant 0.1% Triton pulldown buffer (25mM HEPES, 
150mM NaCl, 2mM sodium orthovanadate, 2mM NaF, plus a cocktail of protease inhibitors)  
was added.  Protein concentration was determined using Bio-Rad’s protein concentration kit.  
Biotinylated proteins were then isolated using ImmunoPure immobilized streptavidin beads 
(Pierce) overnight at 4°C with agitation.  Beads were washed three times with 0.1% Triton 
pulldown buffer and biotinylated proteins were then eluted in 50µL of 2X SDS-PAGE sample 
loading buffer at 95°C and then cooled to room temperature.  Total slice lysates and the 
biotinylated (slice surface) fraction underwent immunodetection for NET (MabTechnoligies Inc. 
Stone Mountain, GA) as described previously.   
 
Synaptosomal uptake.  Mice were sacrificed by rapid decapitation and cortex dissected using an 
ice cold metal block and then homogenized at 400 rpm in at least 10 volumes (w/v) of ice-cold 
0.32 M glucose with a Teflon-glass homogenizer (Wheaton Science Products, Millville, NJ). 
After centrifugation of the homogenate at 800g for 10 min at 4°C, the supernatant was again 
centrifuged at 10,000g for 15 min. The final pellet was gently resuspended in Krebs-Ringer 
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HEPES (KRH) medium containing 118 mM NaCl, 4.8 mM KCl, 25 mM NaHCO3, 1 mM 
NaH2PO4, 1.3 mM CaCl2, 1.4 mM MgSO4, 10 mM glucose, 1 mM tropolone, 0.1 mM 
pargyline, and 0.1 mM ascorbic acid, pH 7.4 and protein concentration assayed. Aliquots (0.2 
ml) of synaptosomal preparations (50 ng of protein) were prepared on ice. DA and NE transport 
assays (5 min at 37°C) were initiated by the addition of [3H]DA or [3H]NE (~100 Ci/mmol, 
Amersham) and were terminated by immediate filtration over 0.3% polyethylenimine-coated 
glass fiber filters using a cell harvester (Brandel Inc., Gaithersburg, MD). The filters were 
washed three times with 1.5 ml of ice-cold phosphate-buffered saline (PBS) and incubated 
overnight in Ecoscint H (National Diagnostics, Atlanta, GA). Radioactivity bound to filters was 
counted using a Beckman LS 6000 liquid scintillation counter. Nonspecific uptake, defined as 
the accumulation of [3H]DA or [3H]NE in the presence of 1 µM desipramine, was subtracted 
from total uptake values to obtain specific uptake values.  
 
TH immunohistochemistry.  Mice (n = 6/genotype) were anesthetized and transcardially 
perfused with 4% paraformaldehyde.  Brains were removed and cryopreserved, and coronal 
sections were cut on a microtome at 40 µm and stained using minor modifications of published 
protocols.  Sections were blocked in 4% Blotto (Nestlé Carnation dried milk), 0.2% Triton-X 
100 in PBS and incubated at 4°C for 3 days with a monoclonal anti-tyrosine hydroxylase 
antibody (Sigma, 1:4000).  Sections were thoroughly washed and then incubated in biotinylated 
anti-mouse IgG (Jackson Immunoresearch, 1:1000) for 60 min.  Avidin-biotin amplification 
(Vectastain ABC Standard, Vector Labs) and 3-3’-diaminobenzidine reactions were used to 
visualize labeled proteins. Sections from all genotypes were processed in parallel to minimize 
variability between groups. Negative controls in which primary antibody was omitted revealed 
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no specific labeling.   Slides were coded so that the investigator was blinded to the genotype and 
sections were imaged using a Zeiss Axioskop microscope and Axiocam HR.  TH-
immunoreactive (IR) cells were counted in images obtained with a 40X objective in two fields 
per hemisphere derived from 2-3 sections per animal.  Values were corrected for cell diameter, 
but no differences in cell diameter were found across genotypes.   
 
Statistical analysis.  All data are expressed as the mean ± s.e.m.  Statistical significance between 
groups was determined using t-tests or one and two-way ANOVAs followed by post hoc tests 
when the main effect or interaction was significant at P < 0.05.  Statistical analyses were 
conducted using software from Graph-Pad Prism.  The number of animals and specific statistical 
analyses used in each experiment are indicated in the results and figure legend sections. 
 
ACKNOWLEDGMENTS: We would like to acknowledge Daniel R. Weinberger for helpful 
discussion and insights during the preparation of these studies.   
 63 
CHAPTER 3 
 
HYPERLOCOMOTION AND DISRUPTIONS IN STRIATAL CATECHOLAMINE 
CONTENT IN THE NEURONAL RICTOR NULL 
 
Abstract 
 
Background/methods:  Based on evidence outlined in the preceding chapter, a compelling 
argument can be made that NET overexpression serves to precipitate cortical DA dysfunction in 
the neuronal Rictor null.  However, abnormal striatal DA function is also a possibility in this 
model, given the link between Akt and disorders of striatal DA signaling, including 
schizophrenia and Parkinson’s disease.  Evidence from prior studies in animal models support a 
link between Akt signaling and the function of mesolimbic/mesostriatal DA networks.  Therefore 
open field locomotion and psychomotor responses to the stimulant AMPH, two behavioral 
phenotypes classically linked to the function of striatal DA networks, were analyzed in the 
Rictor-nKO, along with neurochemical and biochemical assessments of striatal DA function. 
 
Results/Conclusions: A DA-deficiency characterizes striatal DA systems of the Rictor null, 
similar to the phenotypes observed in prefrontal cortical regions.  Behavioral phenotypes 
observed in the Rictor null, however, including open field hyperactivity, and hypersensitivity to 
AMPH, are more typically associated with those observed in functionally hyperdopaminergic 
and hypernoradrenergic models.  Preliminary biochemical data is discussed, although it is non-
conclusive.  The potential role of noradrenergic dysfunction in both basal and AMPH-stimulated 
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locomotion in the Rictor-nKO is also discussed, given the findings of elevated NE and NET 
observed in many of the brain regions studied in the Rictor-nKO.  Post-synaptic mechanisms are 
considered in addition to the pre-synaptic mechanisms that are the basis of this thesis, and 
technical considerations regarding how to make inferences between biochemical and functional 
findings are proposed.  Prospective follow up studies, utilizing pharmacologic and genetic 
methods are described as priorities in order to analyze separate contributions of DA synthesis, 
DA reuptake, post-synaptic signaling and noradrenergic systems to the observed phenotypes.  A 
noradrenergic focus for follow up experiments is particularly encouraged.  Such an approach 
would serve both to validate whether the DA-NE interactions proposed in Chapter 2 additionally 
extends to the regulation of striatal systems that are the focus of this chapter.  Additional study of 
noradrenergic influences on the phenotypes described in this chapter may also help further 
development of noradrenergic agents in clinical practice, including NET inhibitors for cognitive 
enhancement and depression, alpha-1 antagonists for post-traumatic stress disorder, alpha-2 
agonists for hypertension and anesthesia, and DBH-selective inhibitors for cocaine addiction.      
 
Introduction 
 
Aberrant signaling through the protein kinase Akt is an increasingly well-studied mechanism 
underlying neuropsychiatric disease.  While the mechanisms linking Akt signaling to 
neuropsychiatric diseases are manifold, cellular and animal models suggest that dysfunctional 
Akt signaling profoundly influences the machinery underlying DA neurotransmission (Emamian, 
Hall et al. 2004; Lai, Xu et al. 2006).  The preponderance of the evidence suggests that deficits in 
Akt signaling lead to alterations in DA signaling, through a combination of mechanisms 
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including an influence on cell survival and transporter regulation. The initial characterization of a 
novel model of Akt dysfunction, the neuronal Rictor null, recapitulates the influence of Akt 
signaling on DA neurotransmission, at least in cortical brain regions.  Intriguingly, levels of 
tissue NE are markedly elevated in cortical brain regions.  Additionally, Rictor-nKO mice show 
reduced levels of prefrontal DA compared to their wild type counterparts.  Histological 
assessments suggest that this effect is not due to survival, as TH projections to cortical regions 
are equivalent between genotypes, and density of TH cell bodies in SN and VTA are similarly 
analogous.  However, NET levels are markedly different between genotypes, an intriguing 
finding given elevations in NET observed in hypoinsulinemic mice (Robertson, Matthies et al. 
2010).   
While cortical DA dysfunction seems dependent on NET dysfunction in the Rictor-nKO, 
striatal DA neurotransmission remains relatively uncharacterized.  Given recent evidence 
implicating dysfunctional Akt signaling in brain disorders like schizophrenia and Parkinson’s 
disease (Emamian, Hall et al. 2004; Timmons, Coakley et al. 2009), we sought to investigate 
alterations in subcortical DA systems in the Rictor-nKO.  We therefore analyzed two behaviors 
tightly linked to the function of striatal DA systems, namely open field behavior and the 
locomotor activating effects of AMPH (Fahn, Libsch et al. 1971; Davis, Kahn et al. 1991; 
Lotharius and Brundin 2002; Howes and Kapur 2009).  Additionally, we analyzed monoamine 
content in striata of the neuronal Rictor null, and performed biochemical assessments of striatal 
DA systems.  The significance of these findings and prospective experiments to disentangle the 
underlying mechanisms are outlined in the following chapter.    
   
Results 
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Figure 11.  Neurochemical assessment of dorsal striata in Rictor-nKO mice. 
 
Tissue content of (a) DA, (b) NE, and (c) 5-HT, (d) HVA, and (e) DOPAC in dorsal striatum 
homogenates.    Results are presented as mean ± s.e.m ng/mg of protein, n=11-10. *P<0.05; 
***P<0.01 Student’s t-test. 
*
*
n.s.
***
***
a b c d e
 
Reductions in tissue dopamine content in dorsal striatum of Rictor-nKO 
We dissected and evaluated the neurochemical content of striata from several cohorts of 
mice.  Rictor-nKO mice show a 30-40% reduction in both striatal DA content (Fig. 11a, data 
demonstrated Rictor-FLOX versus Rictor-nKO reported as mean ± s.e.m., in ng/mg protein; 
FLOX=95.06 ± 10.97, KO=61.53± 5.904; P=0.016 by Student’s t-test) and its major metabolites, 
namely 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), compared to 
wild type controls (Fig. 11d-e, for DOPAC, FLOX=10.64± 1.028, KO=6.7± 0.508; P=0.0032 by 
Student’s t-test, for HVA, FLOX=12.68± 0.8413, KO=7.47± 0.6993; P<0.001 by Student’s t-
test).  Given that the decreases in DA and its metabolites DOPAC and HVA were of similar 
magnitude, DA turnover rates are not significantly different between genotypes. Importantly, 
5HT levels did not differ significantly between groups (Fig. 11c, FLOX=14.2 ± 0.9002, 
KO=16.72± 1.32; P=0.1189 by Student’s t-test). This suggests that, although signaling through 
mTORC2 is likely to interfere with a range of physiological functions, cortical catecholamine 
systems are particularly disrupted in the Rictor-nKO.    
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The finding of reduced DA in a putative loss of function Akt model is consistent with 
findings from previous studies.  For example, flies lacking the Parkinson’s-related gene DJ-1 
show reductions in both p-Akt and tissue DA content (Yang, Gehrke et al. 2005), dominant 
negative Akt viruses inhibit DA neuron growth and survival (Ries, Cheng et al. 2009), and 
prefrontal regions previously examined in the Rictor-nKO show reductions in tissue DA content 
(Siuta, Robertson et al. 2010).   
Unexpectedly, elevations in striatal NE levels were also observed in Rictor-nKO mice 
(Fig. 11b, FLOX=6.49 ± 0.69, KO=10.49± 1.36; P=0.014 by Student’s t-test).  Elevations in 
tissue NE levels are also observed in cortical regions of the Rictor-nKO (see Fig. 6) and in 
additional brain regions like the hippocampus, hypothalamus, and cerebellum (data not 
published).  However, the significance of elevated NE levels must be interpreted cautiously in 
the Rictor-nKO, as reviews of the literature reveal controversies regarding whether significant 
noradrenergic innervation of the striatum exists.   One side of the argument holds that while there 
may be NE projections to ventral regions of striatum, the projections to the dorsal regions of 
striatum characterized in our study are relatively sparse (Rommelfanger and Weinshenker 2007). 
However, while NE projections to the striatum may be limited compared to NE innervation of 
other brain regions, there is some evidence to suggest a physiological and pathophysiological 
role of NE in striatal function.  For  example, studies of cultured striatal neurons reveals that 
adrenergic receptors modulate DA signaling pathways (Hara, Fukui et al. 2010), and elevated 
striatal NE levels are observed in other pathological mutant models (Raber, Mehta et al. 1997).  
Additional information demonstrating a role of NE in striatal neurotransmission stems from 
studies demonstrating both endogenous NE levels and the accumulation of radiolabeled NE into 
striatal brain regions following intraventricular injection (Glowinski and Iversen 1966).  
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Figure 12.  Locomotor assessment of Rictor-nKO mice in a novel, open field 
environment.   
 
Markedly enhanced horizontal locomotion (12a) and stereotypy (12b) characterize the 
Rictor-nKO, which persists on the first day for a 180 minutes period.  Rictor-nHET mice 
show comparative locomotor activity to wild type animals, suggesting that complete loss of 
signaling through Rictor is required the hyperactivity phenotype that characterizes the 
mutant(data not shown).  
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Furthermore, striatal brain homogenates from canines are capable of synthesizing NE from DA, 
suggesting the presence of the noradrenergic synthetic enzyme DBH in this brain region 
(Udenfriend and Creveling 1959). Therefore, the potential significance of striatal NE in the  
Rictor-nKO, warrants further investigation.  
  
Pronounced open field hyperactivity in neuronal Rictor null (Rictor-nKO) mice. 
 
The implications of a tissue DA deficiency, at the levels of physiology and behavior, are 
markedly different depending on the context of the animal model in which it is observed.  For 
example, both animals with neurotoxic (6-OHDA) lesion of nigrostriatal DA pathways, and mice 
lacking the DA transporter are characterized by reductions in total tissue DA content (Kelly and 
Iversen 1976; Jones, Gainetdinov et al. 1998).  However, these models differ markedly in terms 
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Figure 13.  Locomotor response of Rictor-nKO mice to saline and AMPH.  
Rictor-nKO mice demonstrate enhanced sensitivity to the locomotor activating effects of 
AMPH.   All animals were habituated to the chamber for 6 days before AMPH challenge 
exposure to ensure the locomotor response to saline were equivalent between groups (a).   
Significant activation occurred in Rictor-nKO mice on in response to 2mg/kg of AMPH 
challenge day (b, arrow denotes when AMPH is administered, **p<0.01 by two way ANOVA 
for genotype effects on drug response versus rictor-FLOX animals).    
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of their exploratory behavior in the open field, with 6-OHDA-lesioned mice showing profound 
hypokinesia and DAT-KO mice demonstrating profound hyperactivity (Kelly and Iversen 1976; 
Jones, Gainetdinov et al. 1998).   
Therefore, to gain insight into the relationship between tissue DA concentration and 
locomotor activity in this model, we evaluated the behavior of Rictor-nKO mice in the open 
field.  Compared to control conditions, Rictor-nKO mice demonstrate dramatic elevations in 
locomotor activity (Fig. 12a, P<0.001 for effect of genotype by two way ANOVA), with mutants 
demonstrating an order of magnitude increase in horizontal locomotion that persists for over a 
three hour period.  Additionally, stereotypy shows a similar degree of enhancement in the 
mutants compared to control animals, demonstrating that overall psychomotor activity of the 
Rictor-nKO is dramatically elevated (Fig. 12b, P<0.001 for effect of genotype by two way 
ANOVA). Mice with conditional genetic deletion of one functioning Rictor allele (Rictor-nHET) 
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show comparative locomotor activity to Rictor-FLOX mice (data not shown, P>0.05 by two way 
ANOVA), serving as a control for the effects of the Nestin-Cre transgene and demonstrating that 
complete blockade of Rictor-mediated signaling is required for the phenotypes observed in the 
mutants. 
  
Rictor-nKO mutants are hypersensitive to the locomotor activating effects of AMPH. 
 
 The exaggerated locomotor activity in the Rictor-nKO is intriguing, given that similar 
enhancements in locomotion occur in hyperdopaminergic models like the DAT-KO (Giros, Jaber 
et al. 1996).  DAT-KO mice resemble the Rictor-nKO according to several other key 
phenotypes, beyond this elevation in locomotion.  DAT-KO mice also display PPI deficits at 
baseline that are corrected with nisoxetine (Yamashita, Fukushima et al. 2006).  Intriguingly, 
DAT-KO display paradoxical effects to the psychostimulant AMPH.  As opposed to wild type 
animals, DAT-KO mice demonstrate a reduction in psychomotor activity in response to AMPH 
(Beaulieu, Sotnikova et al. 2006).  Indeed, the response to AMPH is a well-studied phenomenon 
in many models of insulin, PI3K, and Akt dysfunction.  However, there are important 
discrepancies in the literature regarding the influence of Akt on the response to AMPH.  One 
group of findings suggests, collectively, that Akt deficits reduce the locomotor response to 
AMPH, while increases in Akt signaling enhance the locomotor response to AMPH.  
Hypoinsulinemic mice, for example, show diminished self-administration of AMPH (Galici, 
Galli et al. 2003) at particular doses.  Similarly, administration of the PI3K inhibitor LY294002 
reduces the locomotor sensitizing effects of the psychostimulant cocaine (Izzo, Martin-Fardon et 
al. 2002).  Additionally, in vivo voltammetric studies of hypoinsulinemic mice reveal that 
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AMPH-induced striatal DA release is markedly diminished in this model, which is restored with 
local insulin pretreatment (Williams, Owens et al. 2007).  PI3K inhibition causes similar 
reductions in DA release to STZ treatment, suggesting that reductions in AMPH-induced DA 
release are Akt-dependent (Williams, Owens et al. 2007).  In addition to these findings, 
injections of associated adenovirus vectors (AAVs) expressing myr-Akt, a constitutively active 
form of Akt, corrects the AMPH-induced locomotor deficit in  6-OHDA models (Ries, 
Henchcliffe et al. 2006).  This line of evidence suggests, collectively, that a loss of function in 
Akt signaling leads to a diminished sensitivity to AMPH, while gains of function in Akt enhance 
sensitivity to AMPH.   
However, the correlations between Akt signaling deficits and reduced sensitivities to 
AMPH are challenged by separate lines of evidence.  For example, in an analysis of the ability of 
AMPH to affect sensorimotor gating responses, Akt1-deficient mice show a greater sensitivity to 
AMPH-induced disruptions than wild type animals (Emamian, Hall et al. 2004).  Additionally, 
the inhibition of Akt signaling observed in hyperactive mutants and animals given 
psychostimulants is hypothesized to underlie locomotor activity in general.  For example, studies 
of DAT-KO mice suggest that Akt signaling deficits, at least in post-synaptic compartments, 
stimulates locomotor activity, and activation of Akt, in response to medications like lithium and 
the antipsychotics, reduces locomotion (Beaulieu, Sotnikova et al. 2004; Beaulieu, Sotnikova et 
al. 2005).    
Given these discrepant findings in the literature, we sought to test the ability of AMPH to 
modulate open field activity in Rictor-nKO mice.  We first assessed the qualitative effects of 
AMPH administration in a novel, open field environment,.  We found, unexpectedly, that 
administration of AMPH in the open field markedly increased the basal hyperactivity already 
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present in the Rictor-nKO (data not shown).  On initial exposure to the open field, however, 
significant differences in locomotor response to AMPH was difficult to elicit, as baseline 
locomotion is already significantly elevated in this model (Fig. 12).  Therefore, we developed an 
experimental design for AMPH-stimulated locomotion involving a paradigm where each animal 
served as its own internal control in habituated conditions.  This involved analysis of the open 
field activity of the Rictor-nKO every day for 6 days.  Upon reintroduction to the open field 
environment, the hyperactivity of Rictor-nKO mutants persisted, but, on subsequent days, 
eventually habituated to wild type levels after two hours of open field re-exposure (data not 
shown).  By day 6, their locomotor response to saline approached wild type levels, with Rictor-
nKO mice displaying  habituated responses to saline injections (Fig. 13A, P>0.05 for effect of 
genotype by two way ANOVA).  On open field testing on the subsequent day (Day 7) we found 
that locomotor activation in response to AMPH, in terms of both local exploration and 
stereotypic behaviors, was greater in the Rictor-nKO compared to the wild type (Fig. 13B, 
P<0.01 by two-way ANOVA).  This data suggests that, despite what would be predicted by an 
overall reduction in DA content, Rictor-nKO mice are hypersensitive to the locomotor activating 
effects of AMPH.  
 
Discussion/Future directions 
 
The mechanisms underlying the behavioral responses to AMPH are complex.  AMPH is a 
drug that exerts its behavioral influence through elevation of extracellular levels of monoamines.  
A complex array of mechanisms underlie the ability of AMPH to stimulate open field 
locomotion in other models, including TH, the DAT, DA receptors, adrenergic receptors, and 
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even the NET (Tyler and Tessel 1979; Giros, Jaber et al. 1996; Ventura, Cabib et al. 2003; 
Beaulieu, Sotnikova et al. 2004; Beaulieu, Sotnikova et al. 2006; Salahpour, Ramsey et al. 2008).  
Additionally, AMPH is a psychostimulant that, depending on the context of its use, can either 
stimulate or inhibit locomotor activity (Beaulieu, Sotnikova et al. 2006; Alttoa, Eller et al. 2007).  
For example, in DAT-KO mice, which are considered functionally hyperdopaminergic, AMPH 
exerts an inhibitory influence on exploratory activity (Beaulieu, Sotnikova et al. 2006).  In 
contrast, in NET-KO mice, which are considered functionally hypernoradrenergic, AMPH elicits 
a hyperactive locomotor response compared to controls, an effect attributed to development of 
D2 hypersensitivity in this model (Xu, Gainetdinov et al. 2000).   
While AMPH therefore has complex effects on locomotion, the exact relationship 
between Akt signaling and the mechanisms underlying locomotor is unclear, as there are 
discrepant findings in the literature regarding how gains and losses of function in Akt, 
respectively, influence the locomotor response to AMPH.  For example, reduced responsiveness 
to AMPH in an Akt-deficient state is suggested by models of hypoinsulinemia and PI3K/Akt 
inhibition (Izzo, Martin-Fardon et al. 2002; Ries, Henchcliffe et al. 2006; Williams, Owens et al. 
2007).  In contrast, an Akt-deficient state underlying either enhanced locomotor activity or 
sensitivity to AMPH is suggested by DAT-KO mice (Beaulieu, Sotnikova et al. 2004), Akt1 
nulls (Emamian, Hall et al. 2004) and neuronal Rictor nulls on the other (Fig. 13B).   
One potential explanation for these discrepancies is that the source of the Akt signaling 
defect occurs in different cellular populations in these disparate models.  Indeed, in the STZ 
model, which demonstrates reduced AMPH-stimulated DA efflux (Williams, Owens et al. 2007), 
Akt deficiencies are believed to be particularly in pre-synaptic DA neurons, as prior studies 
demonstrate that these neurons express the insulin receptor (MARKS, PORTE et al. 1990).  In 
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DAT-KO mice, however, Akt signaling defects are hypothesized to be in post-synaptic striatal 
neurons (Beaulieu, Sotnikova et al. 2004).  In Akt1 null mice, the signaling deficit involves a 
germline mutation, and thus is present in all cells where Akt1 is expressed (Emamian, Hall et al. 
2004).  Intriguingly, both dopaminergic and noradrenergic systems are particularly prone to 
disruption in Akt1 nulls (Lai, Xu et al. 2006), perhaps due to the fact that the Akt signaling 
defect in this mutant line is systemic, and therefore impacts all neurons expressing Akt1.   
While the exact mechanisms are still unknown, similar disruptions in DA/NE signaling 
are present in the Rictor-nKO, which possibly underlies the altered response to AMPH observed 
in this model.  Indeed, neurochemical findings in both cortical (Fig. 6) and striatal (Fig. 11) brain 
regions suggest that alterations in both systems, namely a DA deficit and a NE excess, 
characterize this model.  A priori hypotheses regarding increased NET expression in the cortex 
of Rictor-nKO mice were confirmed, based off prior evidence in hypoinsulinemic mice.  
Conversely, similar a priori hypotheses regarding decreased DAT expression in the Rictor-nKO 
were also expected, based off findings from hypoinsulinemic mice.  Indeed, while initial 
biochemical assessments suggested that a decreased DAT phenotype was observed in the striata 
of the first Rictor-nKO cohort examined (data not shown), this phenotype was observed in an 
aged cohort, and was not consistently replicated in the younger mice used in the studies 
described in this Chapter (data not shown).   
While a reduction in tissue DAT levels was expected, based on prior studies of Akt-
inhibited/hypoinsulinemic animals, this phenotype, in and of itself, lacks explanatory power for 
the AMPH hyperactivity phenotype in Rictor-nKO mice.  Indeed, prior studies suggest that a loss 
of DAT expression leads to reduced sensitivity to AMPH, rather than enhanced (Giros, Jaber et 
al. 1996; Zhuang, Oosting et al. 2001; Beaulieu, Sotnikova et al. 2006; Williams, Owens et al. 
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2007).  Therefore, in vivo electrochemical assessment of the striatal responses to AMPH was 
attempted in Rictor-nKO nulls, to assert whether particular components of AMPH release, such 
as total amount of DA release, versus DA clearance rates were disrupted in this model.  While 
this approach would  provide insight into the phenoyptes of Rictor-nKO mice at a physiological 
level, these experiments were discontinued due to difficulties of the Rictor-nKO to survive the 
anesthesia involved in study protocol.   
Thus, in vivo microdialysis investigations in the future may be warranted, if carefully 
planned a priori hypotheses are available and proper internal and external controls can be 
established.  Future chronoamperometric investigations into the function of striatal systems in 
Rictor-nKO mice are also warranted, although this model is perhaps better suited to an ex vivo 
assessment utilizing striatal slices as opposed to an in vivo assessment.  Such an approach would 
allow for investigations of DA clearance but free of confounds of genotype by anesthesia 
interactions on the measurements.   
Additional biochemical assessments of TH and striatal DA receptors function in the 
Rictor-nKO were similarly inconclusive.  TH and DA receptors were not different in either 
striatal or cortical regions of this model (data not shown).  However, further pharmacological 
challenge of TH and DA receptor in Rictor-nKO may yield functional insights that are not 
apparent at the biochemical level.  For example, in mice lacking the DAT, TH levels 
biochemically are reduced 95%, but TH at a functional level is markedly upregulated in these 
mutants (Jones, Gainetdinov et al. 1998).   Indeed, many phenotypes characteristic of the DAT-
KO, such as pronounced locomotor activity and elevations in extracellular DA, are dependent on 
these upregulations in TH activity.  Similar findings are also observed at the level of the DA 
receptor in DAT-KO mice.   Biochemically, there are marked reductions of DA receptor at a 
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total level in DAT-KO mice, but aberrant behavioral responses to DA receptor stimulation are 
additionally noted, as, following apomorphine administration, the DAT-KO becomes markedly 
rigid with strong tremor (Raul Gainetdinov, personal communication).  
Therefore, particularly for the synthetic and receptor proteins involved in the response to 
AMPH, functional assessments of the behavioral response to these agents are warranted. The 
contribution of TH activity to hyperactivity in the Rictor-nKO, for example, can be determined 
by measuring the ability of the mutant to generate locomotor activity when challenged alpha-
methyl-tyrosine, an agent that inhibits TH activity. Additionally, the sensitivity of the 
phenotypes in the Rictor-nKO to reagents like apomorphine can provide insight into receptor 
dysfunction in this model.  Observations regarding the behavioral response to these agents, 
therefore, can then guide further lines of experimental inquiry. 
Apart from the classical dopaminergic mechanisms underlying the locomotor response to 
AMPH, an important future direction for the Rictor-nKO involves disentangling the role of 
noradrenergic systems in locomotor and psychostimulant-induced phenotypes.  Indeed, one 
potential explanation for the observed hypersensitivity to AMPH in the Rictor-nKO is the 
noradrenergic phenotype observed in this model.  Rictor-nKO mice demonstrate increased NE 
tissue content, observed in cortex (Fig. 6), hippocampus, hypothalamus, cerebellum (data not 
shown), and striatum (Fig. 11).  Additionally, NET expression is also markedly elevated in this 
model, in cortical regions (Fig. 7), hippocampus, and potentially the striatum (data not shown).  
While the effects of AMPH are traditionally attributed to the DAT, the NET is also a target of 
AMPH action, and both NE and the NET play important roles in behavioral response to AMPH 
in wild type animals.  Prior studies, for example, involving microdialysis assessment of the 
locomotor response to AMPH, demonstrate that cortical NE is a critical mediator of locomotor 
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sensitization to AMPH  (Darracq, Blanc et al. 1998).  Additionally, prior studies also 
demonstrate that pretreatment with selective NET inhibitors like nisoxetine, in wild type animals, 
blocks the locomotor response to AMPH (Tyler and Tessel 1979).   
It is clear that NE in the brain is a significant modulator of the response to AMPH, 
thoughit is currently unclear whether elevations in striatal NE in the Rictor-nKO (Fig. 11) 
contributes to either hyperactivity (Fig. 12) or enhanced locomotor response to AMPH (Fig. 13) 
in the Rictor-nKO.  While controversies regarding the significance of NET innervation of the 
striatum are addressed previously, there is some precedent for the potential physiological 
significance of striatal NE, as recent evidence suggests NE-DA cross-talk occurs in the striatum, 
where adrenergic receptors serve to modulate DA signaling pathways in post-synaptic neurons 
(Hara, Fukui et al. 2010). 
Therefore, one additional direction to consider for future study of the Rictor-nKO would 
be to use appropriately controlled studies with immunohistochemical or in vivo microdialysis 
methods to thoroughly validate whether there is any striatal NE in the Rictor-nKO, as suggested 
by the neurochemical data outlined in Fig. 11.  There is, indeed, some data to suggest there is a 
role for NE in striatal behaviors.  Elevations in striatal NE, for example, have been linked to 
phenotypes of hyperactivity in other mutant models (Jones and Hess 2003).  Additionally, 
microdialysis studies support the existence of NE in striatal brain regions, as previous studies 
suggest that extracellular NE levels are ¼ those of DA levels in this brain region (Cenci, Kalén et 
al. 1992; McKittrick and Abercrombie 2007).  Lastly, while immunohistochemical and 
biochemical data lack in terms of demonstrating NET expression in striatum (Miner, Schroeter et 
al. 2003), uptake studies, utilizing transporter knockouts as important controls, demonstrate that 
selective NET inhibitors affect 20% of DA uptake in this brain region (Moron, Brockington et al. 
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2002).    Indeed, as disruption of both NE and DA systems are observed in other mouse models 
of Akt deficiency, validation of striatal NE transmission in the Rictor-nKO may yield novel 
insights into the pathogenesis of neuropsychiatric disease (Lai, Xu et al. 2006).   
  While the pharmacologic methods outlined above provide one methods to disentangle 
the contributions of various targets of AMPH and neurotransmitter systems, alternative genetic 
methods are also possible.  A possible approach to genetically dissect out the contributors to the 
locomotor response to AMPH, would be to generate Rictor deletions driven by TH-cre, DAT-
cre, and NET-cre, leading to deletion of Rictor in DA and NE neurons, DA neurons, and NE 
neurons, respectively.  Correlation of locomotor, biochemical, and neurochemical phenotypes 
across genetic models would help to dissect out not only the molecular aspects controlling these 
phenotypes, but also more precisely contributions of both neurodevelopmental processes and 
neuroanatomy to the observed phenotypes.  
  It is important to note that, as with other genetic mouse models, diverse neurotransmitter 
systems are likely to modulate the dysfunctional phenotypes observed in Rictor-nKO mice.  
Conversely, the same transgenic animal can be developed to model the phenotypes of seemingly 
disparate conditions.  Indeed, a genetic model like the DAT-KO, when challenged appropriately, 
can model both a hyperkinetic disorder like ADHD (Beaulieu, Sotnikova et al. 2006) or a 
hypokinetic disorder like Parkinson’s (Sotnikova, Beaulieu et al. 2005).  Thus, future evaluation 
of the Rictor-nKO is warranted over time, and in the context of different environmental and 
pharmacological challenges, to fully understand the value of the Rictor-nKO for modeling 
complex human disorders. 
 
Methods 
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Tissue extraction for neurochemistry. Brain sections were homogenized in 100-750 ul of 0.1M 
TCA, which contains 10-2 M sodium acetate, 10-4 M EDTA, 5ng/ml isoproterenol (as internal 
standard) and 10.5 % methanol (pH 3.8).  Samples were spun in a microcentrifuge at 10000 g for 
20 minutes, the supernatant removed and stored at –80 ºC.  The pellet was saved for protein 
analysis.  Supernatant was then thawed and spun for 20 minutes and then analyzed for biogenic 
monoamines and/or amino acids by a specific HPLC assay (Vanderbilt Neurochemistry Core).  
Biogenic amines were eluted in the following order: NE, MHPG, epinephrine, DOPAC, DA, 5-
HIAA, HVA, 5-HT, and 3-MT (2).   
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Figure 14.  Model of postulated changes at catecholamine synapses occurring in Rictor-nKO 
mice. 
 Model for the dysfunction observed in the Rictor-nKO, which is hypothesized to occur as a brain 
adaptation to an Akt-deficient or insulin resistant state.  The figure above depicts a synapse where 
a NE and DA terminal innervate a common post-synaptic target.  Extracellular levels of 
transmitter are assumed to be equivalent between genotypes at this time, although future studies 
are warranted to validate if this is true.  Changes in intracellular content of transmitter between 
genotypes is depicted, in particular less DA (red neuron) and more NE (blue neuron) in the 
Rictor-nKO.  Evidence from biochemical, uptake, and pharmacological studies suggest that a gain 
of function of the NET occurs in the Rictor-nKO (blue arrow), and this gain of function 
particularly impacts DA neurochemistry. A decrease in function of DAT is predicted in the 
Rictor-nKO (red arrow), based off evidence of prior models of PI3K/AKT inhibition, but this 
pathway warrants further investigation in this model.  One novel component of these findings is 
that a minor pathway in DA clearance in wild type animals (dotted red arrow in wild type) takes 
on pathophysiological significance in the Rictor-nKO (red arrow in Rictor-nKO).   Diffusion in 
the extracellular space is not yet understood in the mutant versus wild type animals (black arrow), 
although it can be modeled in future studies.  Functional consequences of loss of mTORC2 
signaling on specific neurotransmitter systems require further investigation in order to fully 
understand the translational potential of this model.     
CHAPTER 4 
 
CONCLUSIONS, FUTURE DIRECTIONS, AND SIGNIFICANCE  
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Implications: Insights into the mechanism of action of the NET  
 
Emerging evidence suggests that DA and NE systems are exquisitely interrelated, with 
disruptions in the regulation of one of these systems causing concomitant dysfunction in the 
other.  DA and NE are the two major catecholamines in brain, and modulate many analogous 
functions, including reward, locomotion, and cognition.  In addition to their shared control of 
brain function, DA and NE derive from a common biosynthetic pathway, with DA serving as the 
precursor for NE.  Synaptic control of both of these transmitters is accomplished by an intricately 
regulated system that includes reuptake by their respective transporters, namely the DAT and 
NET.     
There is significant potential for interaction between DA and NE systems in brain, at the 
level of both transporter and receptor function (Rommelfanger and Weinshenker 2007; Hara, 
Fukui et al. 2010).  At the level of transporter interactions, in prefrontal cortical regions, where 
DAT expression is low (Miner, Schroeter et al. 2003; Liprando, Miner et al. 2004), the NET is 
the major transporter responsible for DA uptake, as inhibition of the NET increases extracellular 
DA levels, as measured by in vivo microdialysis (Yamamoto and Novotney 1998; Moron, 
Brockington et al. 2002).   In the Rictor-nKO model, the evidence outlined in Chapter 2 suggests 
that the relationship between the NET and cortical DA takes on a disruptive role.   
Pharmacological, neurochemical, and biochemical data collectively suggest that a gain of 
function of the NET leads to neurobehavioral and neurochemical defects in this mutant.  These 
findings have significance for the treatment of neuropsychiatric disease, given that disorders like 
depression, schizophrenia, Parkinson’s disease, and drug addiction are prominently linked to 
dysfunction of catecholamine systems and the Akt signaling pathway (Emamian, Hall et al. 
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2004; Arnold, Talbot et al. 2005; Bajestan, Sabouri et al. 2006; Ries, Henchcliffe et al. 2006; 
Cookson, Dauer et al. 2007; Russo, Bolanos et al. 2007; Krishnan, Han et al. 2008; Aubry, 
Schwald et al. 2009; Bitanihirwe, Weber et al. 2010). 
In line with this evidence, and the findings presented in Figures 4-10, we developed the 
model in Fig. 14 to explain the change in the dynamics at cortical synapses that results from loss 
of signaling through mTORC2/Akt, as is hypothesized to occur in numerous disorders of the 
central nervous system.  Fig. 14 depicts a hypothetical synapse where a DAT neuron and a NET 
neuron innervate a common post-synaptic target.  In addition to a DA and NE neuron, arrows 
demonstrating the motion of substrate in the synaptic space are depicted in Fig. 14.  The  
reuptake of DA and NE into their respective presynaptic terminals is depicted by red and blue 
arrows, respectively.  The weighting of the arrows in Fig. 14 represents qualitative differences in 
uptake of DA and NE between genotypes.  Enhanced NET function in the Rictor-nKO, in terms 
of an enhanced ability to take up both DA and NE, as demonstrated in Fig. 7, is represented by 
increased weighting of the blue arrows depicting NE uptake.  In contrast to the gain of function 
of the NET, reductions in tissue DA content (red neuron) are depicted in the dopaminergic 
neurons.  This reduction in DA content is reflected from findings in both striatal (Fig. 11) and 
cortical (Fig. 6) brain regions, and consistent with prior studies showing that loss of Akt function 
impairs presynaptic DA functions (Williams, Owens et al. 2007; Iniguez, Warren et al. 2008; 
Ries, Cheng et al. 2009).    
In addition to the changes in catecholamine content that occurs in the Rictor-nKO, Fig. 
14 also depicts another component of DA homeostasis that is hypothesized to occur, namely 
uptake of DA by the NET (dotted arrow in Fig. 14, wild type). Based off of our findings, this 
pathway of DA homeostasis takes on pathophysiological significance in the Rictor-nKO.  This 
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finding is based off of evidence demonstrating increased desipramine-sensitive uptake of both 
DA and NE into cortical synaptosomes, and the findings that inhibition of the NET both rescues 
behavior phenotypes in the Rictor-nKO and increases total DA levels (Fig. 10).  This evidence 
fits with the ability of the NET to alter DA clearance that is suggested by previous in vivo 
microdialysis and ex vivo synaptosomal uptake studies (Yamamoto and Novotney 1998; Moron, 
Brockington et al. 2002; Miner, Schroeter et al. 2003). 
This potential function of the NET is intriguing given the history of NET inhibitors in 
treatment of neuropsychiatric disease.  The tricyclic class of medications (TCA) are potent 
blockers of monoamine transporters in general, and used to be first line treatments for 
depression.  However, despite the advent of selective serotonin uptake inhibitor classes of 
medications for the treatment of depression, TCAs remain effective alternatives for depressed 
patients that fail current first-line treatments (Zhou 2004).  The combination DAT/NET inhibitor 
buproprion has efficacy as monotherapy for treatment of both depression and cigarette smoking 
(Zhou 2004).  Other recent studies suggest that selective NET inhibitors like reboxetine have 
efficacy for the treatment of depression in patients with Parkinson’s disease (Pintor, Baillès et al. 
2006). Additionally, selective NET inhibitors like atomoxetine are important components of 
treatment for attention deficit hyperactivity disorder, (ADHD) (Zhou 2004), and NET inhibition 
has neuroprotective effects in neurotoxin models of Parkinson’s disease (Rommelfanger, 
Edwards et al. 2007).   
Most studies of NET inhibition in schizophrenia demonstrate modest effects.  No benefits 
on cognitive symptoms have been demonstrated, although indices of cerebral blood flow are 
increased in prefrontal cortex of atomoxetine-treated patients (Bangs, Emslie et al. 2007; Rao, 
Venkatasubramanian et al. 2007; Friedman, Carpenter et al. 2008; Kelly, Buchanan et al. 2009; 
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Poyurovsky, Faragian et al. 2009; Sacco, Creeden et al. 2009; Ball, Warren et al. 2011).   
However, none of these studies employed a design where NET inhibitors were given as 
monotherapy.   Intriguingly, while there has not yet been a demonstrated effect of NET inhibitors 
on primary cognitive outcomes in schizophrenia yet, there is some evidence to suggest that NET 
inhibition prevents the manifestation of extrapyramidal motor defects in patients treated with 
antipsychotic medications (Kelly, Buchanan et al. 2009), an intriguing findings given the 
neuroprotective effects of NE in animal models of parkinsonism (Rommelfanger, Weinshenker 
et al. 2004; Rommelfanger, Edwards et al. 2007).  Indeed, given that depressive and cognitive 
symptoms are part of the prodrome for both schizophrenia and Parkinson’s disease, future 
prospective studies of normal individuals treated with NET inhibitors has value for determining 
the value of the NET in  the manifestation of neuropsychiatric symptoms over time.  
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